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Summary
Models of the outer epithelia of the human body – namely the skin, the intestine and the lung – have found valid 
applications in both research and industrial settings as attractive alternatives to animal testing. A variety of approaches 
to model these barriers are currently employed in such fields, ranging from the utilization of ex vivo tissue to reconstructed 
in vitro models, and further to chip-based technologies, synthetic membrane systems and, of increasing current interest, 
in silico modeling approaches. An international group of experts in the field of epithelial barriers was convened from 
academia, industry and regulatory bodies to present both the current state of the art of non-animal models of the skin, 
intestinal and pulmonary barriers in their various fields of application, and to discuss research-based, industry-driven and 
regulatory-relevant future directions for both the development of new models and the refinement of existing test methods. 
Issues of model relevance and preference, validation and standardization, acceptance, and the need for simplicity 
versus complexity were focal themes of the discussions. The outcomes of workshop presentations and discussions, in 
relation to both current status and future directions in the utilization and development of epithelial barrier models, are 
presented by the attending experts in the current report.
Keywords: in vitro models, epithelial cell culture, permeability, transport studies, cytotoxicity
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1  Introduction
Non-animal models of epithelial barriers are currently enjoying 
increasing interest from various groups, including scientists in 
academia, product developers in industry, regulatory authorities 
and, last but not least, society in general. They play a critical role 
for in vitro to in vivo extrapolation as they feed critical informa-
tion beyond structure and modeling of kinetics (Basketter et al., 
2012; Leist et al., 2014), which is a key element of translating in 
vitro results to a dose paradigm, thus enabling the implementa-
tion of a Toxicology for the 21st Century (Hartung, 2009). While 
ethical constraints, legislation, rising costs and concerns over 
the predictive value of animal experiments may be responsible 
for the altered level of awareness of in vitro models, the interest 
in epithelia as such has primarily to do with the duality and, by 
virtue of this, the importance of their function. Epithelial tis-
sues represent the body’s interface with the “outside world”, 
and therefore must fulfill important biological barrier functions. 
These functions include protecting the body against potentially 
noxious compounds or microorganisms (“outside-in-barriers”), 
as well as preventing the loss of vital compounds such as water 
and solutes (“inside-out-barriers”). The latter function is per-
haps most obvious with respect to the skin epithelium, but is 
also evident for other organs, and particularly notable in cases 
of malfunction as seen in various states of disease (e.g., diarrhea 
or pneumonia with reference to the intestinal and pulmonary ep-
ithelium, respectively). Besides their protective function against 
unintended exposure to chemicals or materials (e.g., from the 
environment or at the workplace), epithelia also provide the 
opportunity to apply compounds on purpose – for example, 
decorative and protective cosmetics, food and dietary supple-
ments, and medical products such as drugs, diagnostic agents 
and vaccines. In the context of medical products, delivery via 
the transdermal, oral or pulmonary routes is non-invasive and 
therefore much preferred over any form of injection (intrave-
nous, subcutaneous, intra-articular, etc.). While similar consid-
erations of course also apply for some more specialized organs 
and epithelia such as the eye, the nose or reproductive organs, 
the predominant routes of either intended or unintended appli-
cation/exposure are the skin, the gastrointestinal tract and the 
respiratory tract. As such, while the need for test methods and 
the considerable progress that has already been made regarding 
other epithelia are acknowledged, this report will focus only on 
the epithelia of skin, intestine and lung (Fig. 1A,B). 
Despite the fact that interest in epithelial barriers is common 
to various applications and industries, each epithelial barrier 
model has both specific characteristics and caveats for applica-
tion. For the safety of cosmetics, chemicals and new (nano!) 
materials, it is most important to show that no harm is done to 
the epithelia to which such compounds are applied intentionally 
or not. In addition, any transport across epithelia, which would 
lead to unintended local or systemic bioavailability, should be 
Fig. 1A: Depiction of the outer epithelial barriers of the human body – the skin, the intestine and the lung
Intended or unintended application of test chemicals to these epithelial barriers may result in either no effect, indicating a successful 
protective action of the barrier; a local effect, occurring at the barrier itself; or a systemic effect, resulting from penetration through the 
barrier structure. Figure modified in part from Ruge et al. (2013) and de Souza Carvalho et al. (2014), with permission. 
Gordon et al.
Altex 32(4), 2015 329
keting approval of drugs is regulated by very strict and complex 
laws worldwide. Besides their quality, the safety and efficacy of 
new products must be extremely well documented and demon-
strated in several phases of clinical testing. Before even enter-
ing clinical trials, preclinical tests must however be passed suc-
cessfully. The entire process from discovery to market typically 
takes 10 years or longer, and costs more than 1 billion €/$ for 
a single new drug molecule. The discovery to market process 
is also associated with extremely high drop-out rates (Hartung, 
2013), an occurrence which is particularly notable in the case of 
new vaccine candidates. Preclinical, highly predictive models 
for use in vaccine development therefore constitute a significant 
and as yet unmet need within the pharmaceutical industry. 
The needs and activities of the food industry are different 
again, in some way “in between” those of pharma and the cos-
metic/chemical industry (Hartung and Koeter, 2008). While 
food products, including dietary supplements or so-called “pro-
biotics,” must of course be safe, there is on the other hand at 
least some expectation regarding their efficacy. The latter – like 
for pharmaceuticals, but unlike for cosmetics and chemicals 
– thus includes assessment of absorption and bioavailability. 
Compared to drugs and medical products however, the regulato-
ry standards for foods are much less stringent. Yet, with the rise 
of new technologies (including but not restricted to “nano”), the 
need to demonstrate safety and efficacy, if only to convince po-
tential customers, is certainly also present in the food industry. 
as small as possible (ideally nil). Quantitative information on 
absorption across the external barriers is also needed to relate 
external exposures to internal (or systemic) threshold values 
in the context of regulatory risk assessment. This approach is 
followed to collectively assess the impact of simultaneous or 
sequential exposures through the different routes, e.g., for pes-
ticides and biocides. It is also important to show that the natural 
barrier function of a given epithelium is not changed as a result 
of application or exposure – not even indirectly, for example via 
the induction of an immunological response – as this would not 
only cause unacceptable local irritation but as its consequence 
also inevitably lead to an increased absorption of potentially 
noxious compounds. Such considerations define the common 
interest of some industry sectors (i.e., cosmetics, industrial 
chemicals, biocides and plant protection products) in epithelial 
barriers in the context of their R&D efforts for new products. 
Marketing regulations in this case are therefore also different 
from those for food or pharmaceutical products.
In contrast, the pharmaceutical industry, interested in new 
drugs and related products, is obliged to demonstrate not only 
product safety, but also efficacy (Rovida et al., 2015). This in-
cludes providing evidence that an active pharmaceutical ingre-
dient (API) becomes biologically available at its intended site of 
action (e.g., inner organ, tissue, cell or receptor), meaning that 
it is able to cross relevant absorption barriers which otherwise 
would limit its bioavailability and therapeutic efficacy. The mar-
Fig. 1B: Development of in vitro models 
of human outer epithelia at a glance
Cell culture devices have improved from 
petri dishes, through membrane-based 
transwell® tissue culture plates, to 
microfluidic tissue culture chips over 
the few last decades. This significantly 
influenced the development of human 
skin (pink boxes), intestine (green boxes) 
and lung (blue boxes) barrier models. 
All three evolved from the monolayer 
culture of respective primary epithelial 
cells or cell lines to subsequent levels 
of organotypic emulation. Skin models 
progressed from keratinocyte monolayers 
to full-thickness air-exposed skin cultures 
on-a-chip. Intestinal models progressed 
from monolayer Caco-2 cell line culture to 
systemic chip-based co-culture with liver 
and tumor cells. lung models progressed 
from alveolar and bronchial epithelial 
barrier cultures to mechanically coupled 
alveolar models on-a-chip. Only a single 
epidermis skin model has been validated 
at an OeCD level so far, fully replacing 
respective animal models. the detailed 
characteristics and impact of each barrier 
model are described in the corresponding 
sections.
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vaccines and cosmetics. A number of EU regulations therefore 
require information on skin penetration, irritation, corrosion and 
sensitization. Within Europe, such regulations for example per-
tain to chemicals (EU, 2006, 2008), biocides (EU, 2012), cos-
metics (EU, 2009a) and plant protection products (EU, 2009b). 
From a pharmaceutical point of view, topical delivery poses an 
important alternative to oral drug administration, which in many 
cases is associated with insufficient intestinal absorption. Deliv-
ery via the skin is also associated with a reduced pre-systemic 
metabolism (first pass), the possibility to achieve sustained drug 
penetration and the potential to avoid drug toxicity as seen with 
oral administration (Bouwstra et al., 2003). Currently there over 
35 transdermal delivery systems are described and approved in 
the EU, USA and Japan (Murthy, 2012; Uchida et al., 2015). The 
use of in vitro diffusion systems to assess skin permeability there-
fore constitutes a useful tool for the development of further novel 
formulations, and for the purposes of toxicity testing and quality 
control. 
The best model to study effects in human skin avoiding any 
species extrapolation would be native human skin. For dermal 
absorption studies excised human skin is the preferred model 
and accepted by many authorities, since the barrier properties 
are well preserved after excision. However, storage in a freezer 
can influence other properties of the skin tissue such as CYP450 
isoenzyme activity (Henkler et al., 2012; Kao et al., 1985); this 
in turn may change the absorption or sensitization character-
istics of a compound. Furthermore, restricted access to human 
material, limited availability and high costs are obstacles to the 
use of native human skin. Such restrictions also provide an ex-
planation for the continuing use of in vivo and ex vivo models of 
animal skin, as well as the growing importance of in vitro recon-
structed human skin models. Artificial skin surrogates (mem-
brane systems with lipids applied on top of these membranes) 
and in silico models have also proven to be helpful when pre-
dicting the in vitro release of the compounds and modelling of 
compounds penetration and toxicity. 
Already in the early 1990’s a number of scientists and institutes 
worldwide focused on the development of alternative methods 
to address topical toxicity, due to several revisions of the Cos-
metics Directive 76/768/EEC. In 2003 a new revision resulted 
in the provision of specific testing and marketing bans related to 
using animals in the safety evaluation of cosmetics. In 2009, the 
new EU Cosmetic Products Regulation (EC) No 1223/2009 was 
adopted and has been fully applicable since 2013 (EU, 2009a). As 
a consequence, most of the in vitro assays available today have 
been developed as replacements dealing with hazard identifica-
tion, and to a much lesser extent, with hazard characterization. 
This chapter reviews the available models for studying the 
skin barrier, skin penetration and topical toxicity in pharmacol-
ogy and toxicology. It gives examples of model employment in 
the various areas and discusses the current problems associated 
with their use. 
2.2  Ex vivo skin models
Ex vivo human skin is usually obtained as a product of plas-
tic surgeries either directly from hospitals or distributed by as-
sociated tissue banks. It is mainly used for the assessment of 
The outcome goal of this workshop and report was to analyze 
the current status of barrier models (skin, intestine and lung) 
in the various areas of application introduced above (environ-
mental chemicals/cosmetics, pharmaceuticals and food). Based 
on such analysis, it became possible to identify specific needs 
for new models, as well as to define further research needed to 
validate existing models. The long term goal in this respect must 
be to create valid, robust alternatives to animal testing. 
2  Non-animal models of the skin  
in research, industrial applications and  
regulatory toxicology
2.1 General introduction
The skin, a complex living membrane, is the largest unfolded 
organ of the human body, accounting for approximately 15-17% 
of the body weight and with a surface area of approximately 
1.5-1.7 m2. Skin is a continuously self-renewing (via repair and 
desquamation), metabolically active organ providing the means 
for detoxification of chemical insults; it is immunologically rel-
evant with regard to sensitization and skin allergies, provides 
a surface that hosts a dense population of microbial commen-
sals (up to 107 CFU/cm2) (Peiser et al., 2012; SanMiguel and 
Grice, 2015), while at the same time protecting the human body 
against adverse microbial colonization. Furthermore, the skin 
protects the body from heat (temperature regulation), water 
(-loss) and electromagnetic radiation. The relationship between 
the structure of the human skin and its mechanical and biologi-
cal barrier properties has been the subject of extensive research 
in the last fifty years (Elias, 1981; Jensen and Proksch, 2009; 
Kirschner and Brandner, 2012; Loewenthal, 1963; Menon et al., 
2012; Norlen, 2001; Wiechers, 1989).
The skin can be depicted as a bilayer organ, consisting of the 
epidermis (outer region) and the dermis (inner region). The avas-
cular epidermis itself is composed of various cell layers, whereas 
the stratum corneum – the outermost layer – is identified as the 
main penetration barrier of the skin (Hadgraft and Lane, 2005). 
This structure consists mainly of dead corneocytes (derived from 
keratinocytes) embedded in lipids. The lower epidermis, the vi-
able layer, poses the second main biological barrier, being both 
metabolically and immunologically active. The dermis is vascu-
larized and innervated (including sensory cells); it also contains 
lymphatics, hair follicles, sweat glands and sebaceous glands. 
Substances penetrating the skin barrier have to pass through the 
lipid matrix of the stratum corneum, which forms a continuous 
structure. Protein-containing corneocytes within this lipid ma-
trix form a hydrophilic second compartment within the stratum 
corneum, and can act as a substance reservoir (Hansen et al., 
2009). Being significantly different from other biobarriers, the 
lipid matrix of the stratum corneum contains ceramides, free 
fatty acids and cholesterol in an approximately equimolar ratio 
(van Smeden et al., 2014; Weerheim and Ponec, 2001).
Information on skin toxicity and (trans)dermal penetration of 
compounds via healthy and diseased skin is of the highest impor-
tance for applied and safety sciences of consumer products, e.g., 
chemicals and their mixtures, plant protection products, drugs, 
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substance via the ex vivo model. Therefore, when using very li-
pophilic substances, for example, the acceptor phase should be 
carefully chosen so as not to affect the model. In such a case, 
the penetration may be very difficult to assess, and the absorp-
tion rate determining the drug effect concentration should be 
handled with care as a result. For toxicological evaluation the 
use of an organic receptor fluid may ensure solubility, but the 
resulting change in diffusion pressure may theoretically lead 
to an overestimation of the absorption for some substances. 
ii) The absence of blood vessels and the variable thickness of 
the dermis in dermatomed skin samples may pose additional 
shortcomings, especially in the case of lipophilic compounds. 
To minimize this effect and improve consistency and compa-
rability, EFSA recommends the use of split-thickness skin of 
200-400/500 µm (EFSA, 2012). iii) The penetration via hair 
channels and sweat ducts may be different ex vivo and in vivo. 
However, although fast absorption via hair follicles can be 
observed for selected molecules, e.g., caffeine (Otberg et al., 
2007), there are indications that the fast absorption via shunts 
dominates the transport through skin only until the lag time for 
intra- or transcellular transport is reached (Scheuplein, 1972). 
Therefore, the overall contribution of absorption via skin ap-
pendages may be limited. iv) The period for which ex vivo skin 
will remain viable is limited. 
In contrast, there are several advantages offered by employ-
ment of ex vivo models of human or animal in place of in vivo 
methods. These include: i) Conditions can be more precisely 
controlled and experiments are easier to perform. ii) Radiola-
beled or presumed-toxic chemicals (e.g., as indicated by chem-
informatics data) can be used. iii) A high number of experiments 
can be run simultaneously. iv) Species-relevant (i.e., human) 
skin can be used, providing the possibility to obtain quantita-
tive data on intra-species variability. v) The impact of particular 
conditions (e.g., release from different vehicles) can be stud-
ied much more precisely. vi) Kinetics can be directly measured 
without dilution in tissue fluids or organs. vii) Removal of ethi-
cal costs by avoidance of animal experiments (as applies to the 
Cosmetics Regulation in the EU) (De Wever et al., 2015). 
An overview of advantages, limitations and needs for excised 
human skin (in addition to other skin models as discussed be-
low) is given in Table 1.
In conclusion, ex vivo dermal absorption testing is a well-
investigated methodology that provides useful results. How-
ever, to reduce further the number of animals used in safety 
sciences, the standardization of ex vivo and in vitro experimen-
tal parameters is imperative (EFSA, 2012; Guth, 2013; SCCS, 
2010; WHO, 2006). Furthermore, due to the increasing demand 
for skin absorption studies (EFSA, 2011, 2012) and the stated 
limitations of the use of excised human skin, robust, sensitive, 
cost-effective and validated alternatives to ex vivo testing are 
of considerable interest. In this sense, validated and regulatory 
body-accepted in vitro assays predicting dermal penetration 
would not only significantly reduce the number of animals used 
in experiments, but also dramatically save costs related to the 
pre-clinical testing of potential drug candidates. 
Notably, different regulatory fields have differing require-
ments regarding acceptance of approach criteria, i.e., while 
percutaneous penetration, as required for the safety evaluation 
of chemicals, plant protection products, pharmaceuticals and 
cosmetics (Danso et al., 2015). Ex vivo skin may be prepared 
in various thicknesses using a dermatome. It is thus available 
as epidermis (split-thickness; approximately 100-400 µm) or as 
full skin thickness samples containing the dermis (depending on 
body location up to 1-2 mm). Deviations in the sample thick-
ness however impact on the penetration of substances into the 
receptor fluid (Wilkinson et al., 2006), and therefore samples 
containing only part of the dermis with a defined thickness are 
preferred for testing by several authorities (EFSA, 2011, 2012; 
OECD, 2011). 
Along with the pig skin model, employed due to its bar-
rier properties comparable to human skin as well as a bet-
ter availability (Herkenne et al., 2006), rat skin is also used 
for dermal penetration studies (Takeuchi et al., 2011). Rat 
skin is mainly employed in the plant protection area, for sys-
temic toxicology studies and in vivo skin absorption studies. 
It has, however, to be noted that rat skin is more permeable 
than human skin (van Ravenzwaay and Leibold, 2004), and 
that skin metabolism differs between human and rat species. 
Thus, results obtained with rat models should be interpreted 
with care (Bartek et al., 1972; Jung and Maibach, 2015; Oe-
sch et al., 2014). However, a triple pack using human in vitro 
data corrected by rat in vivo and in vitro data is an accepted 
refinement option for human risk assessment in the EU. If 
the ratio of rat in vivo:rat in vitro is close to 1, in vitro re-
sults with human skin and the triple pack are also accepted 
in NAFTA countries (NAFTA, 2009).
OECD test guidelines 427 (in vivo) and 428 (in vitro) and their 
associated guidance document No. 28 provide a basic framework 
for the practical methods used for dermal absorption studies, but 
they are not specific to a particular regulatory field or industry. 
Thus, different regulatory bodies may require different types of 
study structure, while some of the national agencies are reluctant 
to accept results from in vitro skin penetration tests in general 
(OECD TG 428). Some authorities have published additional 
guidance for the performance and use of in vitro tests for specific 
product groups, for example EFSA for plant protection products, 
or alternatively have published evaluation criteria, such as for 
cosmetic ingredients by the scientific committee on consumer 
safety of the European Commission (EFSA, 2012; SCCS, 2010). 
For some authorities a high donor-to-donor variability in the 
study is an exclusion criterion. On the one hand, this donor de-
pendency is disadvantageous as it complicates the comparison 
of different studies; however, on the other hand, the inherent 
variability reflects the individual differences as in real life. In 
this respect, research focusing on the identification and defini-
tion of the range of an “average healthy human skin” (as referred 
to in the conclusion of this chapter) would help to standardize 
the method further and allow for comparison between different 
studies. A much simpler step in this direction is the performance 
of an accompanying integrity test that ensures the exclusive use 
of intact skin samples as well as skin samples with comparable 
properties (Wiegand et al., 2014; Guth et al., 2015). 
Other limitations of ex vivo absorption studies are as fol-
lows: i) The receptor fluid may influence the transfer of the 
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Tab. 1: Models for dermal absorption
Excised skin
Reconstructed 
human skin 
models
Artificial skin 
surrogates
– human
– rat
– pig
– epiDerm™ 
(Mattek)
– EpiSkin™ 
(l’Oréal)
– SkinEthic™ 
(SkinEthic 
laboratories)
– StrataTest® 
(Stratatech)
– Phenion®Ft 
(Henkel)
– Graftskin LSE™ 
(Organogenesis)
– skin-PAMPA 
(Pion)
– Strat-M (Merck 
Millipore)
– regulatory 
accepted for 
plant protection 
products and 
defined product 
groups (eU)
– screening
– native tissue
– relevant species 
addressable
– spectrum of 
donor and body 
region-specific 
sensitivities
– metabolically 
competent
– easily available, 
standardized, 
reproducible 
– metabolically 
competent
– human derived
– applicable for 
screenings? 
– reflects mixture 
effects (?)
– easily accessible, 
standardized, 
reproducible 
– screening for 
aqueous dilutions
– limited 
acceptance in US
– limited 
acceptance for 
defined product 
groups  (also eU)
– species 
extrapolation 
necessary in case 
of animal skin
– overpredictive 
versus in vivo 
(based on, e.g., 
artificial receptor 
fluid to ensure 
solubility)
– limited availability, 
high costs and 
donor variability 
in case of human 
skin
– overpredicts 
absorption (not 
applicable for risk 
assessments)
– technical 
limitations (low 
stability, transition 
in diffusion 
cells, adsorptive 
underlying 
membrane, 
dependence on 
shipment)
– limited 
applicability 
for screening 
purposes ?
– technical 
limitations (only 
aqueous solutions, 
sufficient water-
solubility, UV-
activity needed)
– no metabolism
– applicability for 
mixtures not yet 
shown
– definition of acceptance 
criteria (e.g., reference 
datasets, integrity 
tests,...?)
– higher standardization 
of the method including 
standardized integrity 
tests (SOP?)
– reduce overpredictivity 
(optimize IVIVC)
– “what is normal”
– define reference 
compounds and 
acceptable inter- and 
intra-laboratory variability 
(ring-trial)
– better understanding 
of barrier formation and 
function (different species, 
role of tight junctions etc.)
– definition of acceptance 
criteria (e.g., reference 
datasets, integrity 
tests,...?)
– higher standardization 
of the method including 
standardized integrity 
tests (SOP?)
– reduce overpredictivity 
(optimize IVIVC)
– “what is normal”
– enhance barrier function 
and stability
– solve technical problems 
– enable application 
for screening and risk 
assessments
– “validation” against highly 
standardized results for 
reference compounds with 
excised human skin
– definition of acceptance 
criteria (e.g., reference 
datasets, integrity 
tests,...?)
– higher standardization 
of the method including 
standardized integrity 
tests (SOP?)
– optimize IVIVC
– show stability against 
formulation ingredients
– prediction of mixture 
effects needed
– in vitro skin 
absorption for 
plant protection 
products in US, 
accepted if  
IVIVC is given  
for the rat
– regulatory 
use of excised 
skin: exposure 
estimates, 
estimates on 
skin absorption 
and penetration 
(cosmetics  
and ReACH)
 Examples Advantages Limitations Issues and needs Memo
Models for dermal absorption
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Gene knock-down tissues, reporter tissues, wound models 
and models populated with various pathogens have also been 
described in the literature (Geer et al., 2004; Jansson et al., 1996; 
Kuchler et al., 2011; Popov et al., 2014; Poumay and Coquette, 
2007; Zhai et al., 2007; van Drongelen et al., 2013). Reconstruct-
ed human skin models for therapeutic purposes (grafting) have 
additionally been described since the 1970s, several of which 
have been commercialized (Tab. 2d).
The use of HSE is not necessarily cheaper than animal ex-
periments or the use of ex vivo skin, however human-derived 
reconstructed tissues used under defined test conditions of-
fer several advantages: i) since most models are composed of 
primary human cells, inter-species extrapolation is avoided; 
ii) in contrast to ex vivo human skin, repeated application of 
formulations can be performed for at least several weeks; iii) 
work with the commercially available epidermal HSE does not 
require advanced knowledge of cell culture techniques (mod-
els are delivered “ready to use”); iv) (three-dimensional-)RhE 
models manufactured for regulatory testing purposes are highly 
standardized, and quality controls are established as requested 
by the OECD TG 431 and 439; v) HSE are readily commer-
cially available in most of the EU, USA and Asia, or can be 
constructed according to available literature as “open source” 
tissues; vi) several RhE models are accepted in a regulatory 
sense for skin irritation and corrosion testing of chemicals, as 
well as for assessment of phototoxicity as one component of a 
drug testing strategy; vii) the employment of HSE leads to the 
reduction of laboratory animal use in regulatory toxicology as 
well as in preclinical studies.
The main shortcomings related to the currently available 
reconstructed tissue models are: i) insufficient barrier proper-
ties, reflected in a modulated lipid composition and organiza-
tion (Leroy et al., 2014, 2013; Thakoersing et al., 2012, 2013) 
and increased flux or absorption rate in skin penetration studies 
(Davies et al., 2015; EFSA, 2012; Hui et al., 2012; Schafer-Ko-
rting et al., 2008); ii) lack of vascularization, sweat glands and 
hair; iii) lack of representation of the physiologically-relevant 
desquamation process; iv) lack of reproducibility of immuno-
competent models.
for the chemical and crop industry overestimation of an effect 
may not represent a problematic issue (due to the aim of pro-
tection of the workers and consumers), for the pharmaceutical 
industry precise prediction of the penetration via healthy and 
compromised skin has consequences for the development of 
the new drugs. 
2.3  Reconstructed in vitro human skin models 
Reconstructed human “skin” models are usually fabricated from 
non-transformed human epidermal keratinocytes, grown either 
on artificial membranes in plastic inserts or on a dermal compo-
nent (artificial or biological matrix). These in vitro cultures are 
in general (whether full or partial thickness models) referred 
to as human skin equivalents (HSEs). HSEs which specifically 
model the epidermis and, as such, consist only of differentiated 
keratinocytes on an artificial membrane, are known as recon-
structed human epidermis models (RhEs). RhEs closely mimic 
the morphological, biochemical and physiological properties 
of the human epidermis, and can be relatively easily created 
in laboratories by following precedents in published litera-
ture (open source models); they have also been commercially 
available for more than 20 years (Tab. 2a). Characteristics of 
the commercially available tissue models are also generally 
well described in the literature (Eckl et al., 2014; Netzlaff et 
al., 2007, 2005; Ponec et al., 2002, 2001; Schaefer-Korting 
and Schreiber, 2008; Schmook et al., 2001; Shevchenko et 
al., 2010; Welss et al., 2004; Cannon et al., 1994; Rosdy and 
Clauss, 1990; Tinois et al., 1994) although not all details are 
disclosed in published work. 
More complex tissues, composed of combinations of two or 
more cell types and/or at least two “skin” layers (epidermis and 
dermis), forming as a result either healthy or diseased models of 
human skin, are also available (Bannasch et al., 2005; Semlin et 
al., 2011; Zhang and Michniak-Kohn, 2012; El Ghalbzouri et al., 
2009; Nischt et al., 2006; Ponec et al., 2003; van den Bogaard et 
al., 2014) (Tab. 2b,c). The most commonly used combinations 
for formation of complex tissue models are those of fibroblasts 
with a dermis model, or keratinocytes with an epidermis model 
– so-called full thickness models.
Tab. 1: Models for dermal absorption
In silico models – Potts and Guy, 
1992
– Abraham and 
Martins, 2004
– Riviere and 
Brooks, 2007
– Guth et al., 2014
– Dancik et al., 
2013
– no experiments  
 needed
– time and cost 
effective 
– screening for 
aqueous dilutions
– limited 
applicability 
domain
– no general 
mixture model 
available
– mechanistic insights in 
dermal absorption and 
mixture effects
– prediction of dermal 
absorption from different 
mixtures
 Examples Advantages Limitations Issues and needs Memo
Models for dermal absorption
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vivo human skin, the absorption ranking of substances does re-
flect results obtained with human skin (Schafer-Korting et al., 
2008). Furthermore, the results obtained with skin constructs 
were less variable than results with excised human skin; the 
transferability of the protocol between the skin models and the 
influence of the vehicle was also reflected (Schafer-Korting et 
al., 2008). 
The improvement of HSE barrier properties is certainly the 
subject of current and future research and may in fact be en-
hanced by modulation of culture conditions; however, it must 
be emphasized that until the barrier properties of HSEs can ap-
proximate those of human skin, minimizing the current over-
predictability, a formal validation and regulatory acceptance 
of HSEs for dermal absorption studies is not feasible. There-
fore, further research is needed to understand the processes 
and mechanisms underlying the human skin barrier, which 
may then inform respective options for tissue engineering. Im-
provement of the barrier function of HSEs could increase the 
overall stability of the tissue, allowing for processes such as 
washing, swabbing and tape-stripping, which are at the current 
stage not feasible, and rendering such models more suitable for 
permeation studies. Further practical aspects that need to be 
addressed for a routine application of HSEs are tissue size, the 
possibility to transfer or adjust models to automated systems, 
storage possibilities and the assessment of the influence of the 
underlying synthetic membrane as an additional, adsorptive 
barrier (Guth, 2013). 
A parameter of additional importance to barrier function is 
the metabolic competence of reconstructed human skin models. 
In this respect, HSEs show advantages when compared to, e.g., 
frozen pig skin, frozen human skin or membrane systems (de-
scribed later in this chapter). It has been shown that cutaneous 
biotransformation can inactivate toxic agents; however, at the 
same time, biotransformation may also contribute to sensitiza-
tion and genotoxicity. Comprehensive investigations into the 
expression and functionality of enzymes involved in cutane-
ous biotransformation of xenobiotics in human skin ex vivo as 
well as in reconstructed tissue models are ongoing, and knowl-
edge continues to improve (Gotz et al., 2012; Huh et al., 2010; 
Oesch et al., 2014). Pre-validation studies have in fact been 
conducted with HSEs to address genotoxicity (Brinkmann et 
al., 2013; Fautz et al., 2013) and skin metabolism (Schafer-Ko-
rting et al., 2006). Two in vitro genotoxicity approaches using 
three-dimensional skin models have been proposed: i) the hu-
man reconstructed skin micronucleus (RSMN) assay using the 
EpiDerm™ model, and ii) the Comet assay, which detects com-
plementary DNA damage, including damage indicative of the 
occurrence of gene mutations (EpiDerm™, Phenion™). Both 
models are currently evaluated in a validation study coordi-
nated by Cosmetics Europe (Aardema et al., 2010; Reus et al., 
2013). Once validated, the RSMN and the three-dimensional 
skin Comet assay may be used as follow-up tests for positive 
results from the current in vitro genotoxicity test battery in a 
weight-of-evidence approach.
In terms of skin sensitization, a lack of reproducible HSEs 
has led to the development of the less integrated but hopeful-
In spite of these shortcomings, reconstructed human tissue 
models are commonly employed for the purposes of regula-
tory toxicological testing. The reconstructed epidermis models 
EpiDerm™, EpiSkin™, SkinEthic™ and epiCS™ (EST-1000) 
have gained acceptability as suitable alternative models for 
skin corrosion testing as a result of extensive validation stud-
ies (OECD TG 431); these models have also recently gained 
approval for sub-categorization of corrosive classes (OECD, 
2014). Similarly, EpiDerm™, EpiSkin™, SkinEthic™ and La-
bCyte™ models are considered as acceptable setups for skin 
irritation testing (OECD TG 439 (OECD, 2013)). A validation 
study addressing the skin irritation and sensitization potency 
of extracts from medical devices is furthermore underway (Ca-
sas et al., 2013; ISO, 2010; Coleman et al., 2015). Another 
example for the successful use of RhE is the phototoxicity 
assessment of topically applied substances and formulations, 
as demonstrated in the pre-validation study of the EpiDerm™ 
model (Liebsch et al., 1999). The use of RhE was furthermore 
recently implemented into the updated ICH S10 guideline for 
the assessment of the phototoxic potency of topically applied 
drugs (EMA, 2012). 
An important point which remains to be addressed, how-
ever, is the matter of the barrier properties of reconstructed 
human skin models. The barrier function of HSEs is still not 
thoroughly described, making it difficult to credibly extrapo-
late determined penetration rates from in vitro data to the in 
vivo situation. Although all lipid classes present in native hu-
man skin are also present in HSEs, there is a deviation in free 
lipid composition and organization compared to native human 
skin. The most important of such deviations are a high level of 
unsaturated fatty acids, shorter lipid chain lengths (Mojumdar 
et al., 2014; Thakoersing et al., 2013, 2015) and an imbalance 
in the level of ceramide subclasses (Thakoersing et al., 2012). 
These changes in lipid composition are expected to contribute 
significantly to the impaired skin barrier of HSEs (Mojumdar 
et al., 2014). With respect to the bound lipid profile, this is 
similar to that of native human skin (Ponec et al., 2003) – 
however, it must be stated that measurements of this profile 
have been conducted with a lower level of precision. Further-
more, the presence of a leaky cornified envelope would also 
contribute to a reduced skin barrier property; while almost no 
data have been reported to date on the protein composition of 
the cornified envelope in HSEs, it has been shown that some 
cornified envelope proteins are expressed differently (involu-
crin) in the models as compared to native human skin (Ma-
laisse et al., 2014). 
HSEs (as well as the previously discussed rat skin) seem 
to overestimate compound penetration by a factor unrelated 
to compound molecular weight, lipophilicity and/or aqueous 
solubility. Notably however, using a strictly controlled protocol 
conforming to OECD test guideline no. 428, a validation study 
with three different RhE models – EpiDerm™, EpiSkin™ and 
SkinEthic™ – indicated their general suitability for in vitro ab-
sorption studies, both in infinite and finite dose experiments 
(Schafer-Korting et al., 2008). Though the permeability rate 
determined using RhEs seems to exceed that found using ex 
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Mitra et al., 2013; Eves et al., 2003; Li et al., 2011; Tjabringa 
et al., 2008). 
As can be seen, reconstructed tissue models already provide 
valuable contributions to basic research as well as regulatory 
toxicology, and in light of the aforementioned progress, they 
continue to possess great potential for further applications. 
2.4  Chip technology 
The need for a high throughput testing approach in the areas 
of toxicology and pharmacology is motivating a number of re-
search groups to develop organs-on-a-chip platforms as well 
as bioreactors (e.g., DARPA, USA; Human-on-a-Chip project, 
EU) (Hartung and Zurlo, 2012). Such a technology could allow 
for future high-throughput screening of novel drug candidates 
or for testing interactions of multiple organs in one experimen-
tal apparatus. Excised tissue, reconstructed tissue and cells lines 
are applicable for this purpose. 
HSE can be produced in various sizes from very large samples 
(4 cm2) for skin penetration studies in classic Franz cells to sizes 
of less than 0.1 cm2 (96-well plates). Adjustment of the HSE and 
their implementation into the miniaturized conditions employed 
in chip technologies or into the environment of a perfused biore-
actor is therefore feasible. In a recent study, scientists from TU 
Berlin demonstrated that perfused systems using reconstructed 
ly more predictive co-culture systems, and also to a focus on 
the specific role of keratinocytes in skin sensitization events. 
Despite a lack of immune cells in the currently commercially 
available tissue models, there are indications that assessment 
of cell viability markers in combination with gene expression 
and direct reactivity (e.g., via the SenCeeTox method (McKim 
et al., 2010, 2012) and Sens-IS method (Cottrez et al., 2015)) 
could be predictive of both the risks as well as potency of skin 
sensitizers (Reisinger et al., 2015). Another approach focuses 
on the investigation of IL-18 production by keratinocytes in 
order to assess the in vitro sensitization potential of low mo-
lecular weight chemicals (Corsini et al., 2009, 2013; Guyard-
Nicodeme et al., 2015).
The use of reconstructed human skin models in pharmacol-
ogy is associated with evaluation of the activity of drugs, in-
cluding estimation of their adverse effects, in healthy as well as 
diseased skin. Studies describing the effects of long-term use 
of glucocorticoids in HSEs, which were found to be as suitable 
models, have been described (Gysler et al., 1999; Lange et al., 
2000; Lombardi Borgia et al., 2008). As another example, spe-
cific HSEs have been developed to simulate the disease con-
ditions of psoriasis and skin cancer (Tab. 2c), and utilized to 
further estimate effects and suggest possible treatments in such 
cases (Berking and Herlyn, 2001; Chamcheu et al., 2015; Datta 
Tab. 2: Commercially available reconstructed epidermis models
Name Manufacturer Comment
a) Commercially available reconstructed epidermis models with regulatory acceptance* – models of healthy human skin
EpiDerm™ MatTek Corp. and MatTek IVLSL OECD TG 431, EU B.41, OECD TG 439, EU.B46, ICH S10 
EpiSkin™ and SkinEthic™ SkinEthic Laboratories OECD TG 431, EU B.41, OECD TG 439, EU.B46, ICH S10 
EpiCS Cell Systems OECD TG 431
labCyte J-teCH OeCD tG 431
b) Commercially available reconstructed skin models (FT-models and/or models combining at least 2 cell types) – models of 
healthy human skin
EpiDerm - FT MatTek Corp. Keratinocytes, fibroblasts (full thickness)
Phenion - FT Henkel Keratinocytes, fibroblasts (full thickness)
FTM/FDM Biomimiq  Keratinocytes, fibroblasts
Melanoderm Mattek Corp. Keratinocytes, melanocytes 
RHPE SkinEthic Laboratories Keratinocytes, melanocytes
EpiCS Cell Systems Keratinocytes, melanocytes
c) Diseased tissue models
Psoriasis Mattek Corp. Model of psoriatic skin
Melanoma  Mattek Corp. Model of skin cancer dermatitis
AD-model FU-Berlin, Biomimiq Model of atopic dermatitis
d) Reconstructed tissue models for grafting (therapeutic purposes)
Graftskin™LSE™ Organogenesis Inc.  For grafting
EpiDex and EuroSkin EuroDerm  For grafting
StrataTech™ Stratatest Keratinocytes, fibroblasts (full thickness) for grafting
*due to the number of available Rhe tissue models, only those with regulatory acceptance are depicted. the regulatory acceptance is 
limited to certain endpoints/OeCD guidelines stated in the “Comment” column. 
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compounds, but not yet for regulatory purposes; to date, a good 
correlation of Kp values derived from skin-PAMPA and excised 
human skin has only been shown for pure or aqueous solutions 
(Guth, 2013; Sinko et al., 2012) and, as mentioned above, such 
a level of correlation is not expected to extend to the testing of 
formulations. 
2.6  In silico modeling
In general, in silico modeling is defined as predictions achieved 
by computer simulation or regression (Hartung and Hoffmann, 
2009). Broadly speaking, all computer models are based on 
mathematical algorithms, with epithelial transport as described 
originally by mathematical principles (such as those espoused 
by Fick (passive diffusion), Michaelis and Menten (active 
transport), Hodgkin (ion transport), Huxley and Katz (solute 
structure), all based on membrane principles originally detailed 
by Meyer and Overton) now precisely defined in terms of a 
number of physicochemical parameters, including solute size, 
shape, polarity and flexibility. The rapid evolution of digital 
technology, high performance computing and big data has al-
lowed epithelial transport to now be described accurately and 
rapidly in three-dimensional space over time and for precise 
constants, characterizing the transport processes to be derived 
by regression and applied to other solutes and epithelia. As 
a consequence in silico modelling has evolved to become an 
important component of non-animal testing methods, with in 
silico pharmacokinetic-pharmacodynamic model analysis be-
ing increasingly used in the regulatory evaluation, approval and 
personalized use of drugs.
Topical products are known to have existed since the dawn of 
time and have evolved through empirical dosage forms, sophis-
ticated manufacturing and appropriate in silico, in vitro as well 
as in vivo studies to provide the range of sophisticated products 
on the market today (Pastore et al., 2015). Various mathematical 
and quantitative structure penetration models have been used 
to describe percutaneous absorption over the ages, directed 
particularly by the work of Takeru and William Higuchi, Alan 
Michaels and Robert Scheuplein in the 1960s and 1970s (Rob-
erts, 2013; Scheuplein, 2013; Scheuplein and Blank, 1971). The 
use of (quantitative) structure-activity relationship (or (Q)SAR) 
models to estimate aspects of skin irritation, corrosion and sen-
sitization has also been in practice for many years, with corro-
sion being related to the relative uptake of compounds within 
a given class of potentially corrosive compounds, such as the 
phenols and acids (Roberts et al., 1977), and irritation related 
to the reactivity of solutes with macromolecules in the viable 
epidermis and dermis (Golla et al., 2009; Hayashi et al., 1999). 
Development and use of (Q)SARs is however always empirical, 
due to a lack of understanding of the underlying biophysical and 
biochemical mechanisms of exposure, disposition and metabol-
ic pathways. (Q)SAR models are limited by the defined applica-
bility domain for which such a system can be used, and as such 
(Q)SARs are always seen as a component of the testing strat-
egy in the particular field. (Q)SAR models have generally been 
developed for small datasets of specific groups of compounds, 
although in some cases more diverse and larger datasets have 
also been examined. The usual parameters that are used in the 
human tissue provide better platforms for increased longevity 
of in vitro skin equivalents, and improve the tissue architecture 
if combined with underlying subcutaneous tissue. In addition, it 
has been shown that skin models can be co-cultured with other 
organ equivalents, such as liver, over periods of at least 28 days 
(Atac et al., 2013; Wagner et al., 2013). 
2.5  Synthetic membrane systems
Other approaches aimed at gaining preliminary permeability 
data in vitro include the artificial membrane-based PAMPA 
(Parallel Artificial Membrane Permeability Assay), discussed 
in more detail in the following chapter in the context of non-
animal intestinal models (Avdeef et al., 2007, 2008; Flaten et 
al., 2006b, 2007; Kansy et al., 1998, 2004), as well as Strat-
M™, available from Merck. The first commercially available 
PAMPA for performing penetration studies is the skin-PAMPA, 
as supplied by Pion Inc. Skin-PAMPA consists of a complete 
test system, including UV reader, as well as required technical 
support and is already in use for determination of temperature 
and protein-binding effects, for evaluation of new compounds 
and for predictive approaches studying quantitative structure-
permeability relationships (Akamatsu et al., 2009; Bujard et al., 
2014; Dobricic et al., 2014; Markovic et al., 2012; Vizseralek 
et al., 2014; Vucicevic et al., 2015). In contrast, the skin-mim-
icking artificial membrane setup Strat-M™ (Merck Millipore, 
USA) is composed of multiple layers of polyether sulfone, 
which is compatible with Franz chamber setups. A study ad-
dressing the applicability of the Strat-M™ approach, involving 
comparison of the permeability coefficients (Kp) of 14 chemi-
cal compounds in a Strat-M™ model with those found using 
excised human and rat skin, could show that the Strat-M™ ap-
proach appeared to be useful for prediction of permeability of 
compounds with a molecular weight between 151 and 288 g/
mol and an octanol/water coefficient (log Ko/w) between -0.90 
and 3.53 (Uchida et al., 2015). 
While both PAMPA and Strat-M™ approaches exhibit con-
siderable advantages for permeability assessment, they also nat-
urally possess some limitations. For example, the composition 
and fluidity of PAMPA artificial membranes does not accurately 
mimic the physiological situation (Avdeef et al., 2001; Seo et 
al., 2006; Tanaka and Sackmann, 2005), as it does not contain 
all the barrier lipid subclasses present in human skin. Further-
more in those cases in which formulations are tested and the 
interaction between the formulation and the membrane has an 
effect on permeability, the predictive power of such approaches 
is expected to be limited. Additionally, PAMPA filters may be-
come blocked, leading to inaccurate permeability data (Avdeef 
et al., 2001; Hamalainen and Frostell-Karlsson, 2004; Seo et 
al., 2006). These factors and possibilities lead inevitably to sig-
nificant differences in permeability study outcomes (Chilcott et 
al., 2005; Frum et al., 2007; Khan et al., 2005) when compared 
to data present in the Flynn permeability database (Parnas et 
al., 1997, 1998). Furthermore, only Kp values presenting the 
permeation rate can be determined – the absorbed dose or the 
remaining compound in the skin layers, which are both relevant 
parameters for toxicological evaluation, cannot be predicted. 
Skin-PAMPA results can be used to prioritize and rank different 
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Chen et al., 2008a). With the mechanistic modeling approach, 
the transport and disposition properties of epithelia can be de-
termined separately, e.g., by molecular dynamics simulation of 
chemical binding to keratin at the sub-cellular level (Marzinek et 
al., 2014). This represents significant progress of simple perme-
ability models. It has been demonstrated that such mechanistic 
models are fully capable of predicting absorbed dose and subcel-
lular distribution of chemicals from formulated products under 
in vivo exposure conditions (Lian et al., 2010). 
2.7  Conclusion 
To answer the question of what is needed to improve the cur-
rently available skin models, assays and test systems we first 
have to better understand the characteristics of a typical, “aver-
age” healthy human skin. Large scale studies focusing on the 
barrier properties of normal skin, skin metabolism, and poten-
tial for development of skin inflammation and irritation, sensi-
tization and particularly skin diseases are required to define a 
normal, standard range that accounts for inherent donor vari-
ability. Such multidisciplinary research also needs to investigate 
detail that includes, but is not limited to, the average number 
of epidermis layers, tight junctions, cornified envelope compo-
sition, lipid composition and lipid organization in the stratum 
corneum in both healthy and diseased skin (taking into account 
genetic profiles and medication histories) and, finally, should 
also establish absorption profiles of representative marker mol-
ecules (i.e., for exposure and effects). A better understanding 
of the structures and mechanisms that determine dermal uptake 
and lead to toxicity events in human skin or even to disease 
conditions is of crucial importance when developing assays for 
testing drug candidates, active ingredients, chemicals and their 
mixtures or formulations. Moreover, such large epidemiologi-
cal studies focused on characterization of human skin would 
ultimately bring unique knowledge backed by statistical power, 
and consequently also reference data needed for development 
of better in silico models and reliable assays, while accelerating 
the process of their formal validation – an achievement that is 
often hindered by a lack of reliable in vivo reference data. 
It should also be noted that the currently available assays are 
inherently limited to substances applied topically, and as such 
do not allow for assessment of substances deposited intrader-
mally. While the latter is a relatively rare circumstance, it is rel-
evant, for example, in the case of tattoo inks. Long neglected 
by toxicologists and regulators, tattoos have increasingly lost 
their maverick image and are about to become a mainstream 
accessory, with up to 36% of adults under the age of 40 hav-
ing at least one tattoo. Although this clearly makes them toxi-
cologically relevant, we know very little about the metabolism 
and toxicology of the colorants and additives used in tattooing 
(Laux et al., 2015). 
Also, the commonly applied eukaryo-centric perspective of 
toxicology makes it easy to forget that skin-associated metab-
olism does not necessarily stop at the epidermal surface, but 
potentially also includes the metabolic and signaling activity 
of vast numbers of skin commensals. An increasing number of 
studies show that the microbiota can have a profound impact 
on the human immune system, as well as on general wellbeing 
development of (Q)SAR algorithms are compound molecular 
weight, melting point, aqueous solubility, vapor pressure, log 
Ko/w, pH, surface tension, and lipid solubility. With respect to 
skin sensitization, protein/electrophilic reactivity and the pres-
ence of alert groups are also of particular importance. 
From the scientific literature, it appears that irritation and 
corrosion endpoints have largely been modeled on a separate 
basis. This is likely due to the fact that corrosion is consid-
ered to be more a physical effect (which can be captured by 
a simple description of acidity or basicity) than a biologically 
mediated effect such as skin irritation. One of the earliest (Q)
SAR approaches to predict skin irritation is based on the TOP-
KAT methodology, however other methods such as BfR-DSS, 
DEREK and MultiCASE are well described, and approximate-
ly 20 additional models have been reported in the literature 
(ECHA, 2014). An overview of the systems developed for skin 
irritation and corrosion is provided by Saliner et al. (2006). 
In the area of skin sensitization, the available (Q)SAR models 
are either chemical class-based/mechanism-based (local mod-
els), or are derived empirically using statistical approaches (glo-
bal models). Some of these available (Q)SARs have been en-
coded into expert, knowledge-based systems that are available 
for the prediction of skin sensitization (e.g., Derek for Windows 
(DfW)), statistical systems (e.g., TOPKAT, MCASE) and hybrid 
systems (e.g., Tissue Metabolism Simulator (TIMES)). Com-
prehensive reviews and evaluation of expert systems, SARs and 
QSARs are available from ECETOC and in the form of publica-
tions from Patlewicz et al. and Teubner et al. (ECETOC, 2003; 
Patlewicz et al., 2008; Teubner et al., 2013). 
Various overviews of in silico models for dermal absorption 
of chemicals can also be found in the literature (Fitzpatrick et 
al., 2004; Geinoz et al., 2004; Moss et al., 2002; Dumont et 
al., 2015). However, to date none of the available models are 
deemed acceptable from a regulatory viewpoint (EFSA, 2012; 
OECD, 2011). This is basically due to four reasons: i) Many 
reported models are focused on the prediction of permeability 
coefficients and not the absorbed dose (the relevant parameter 
for regulatory use), and often employ data devoid of appropriate 
cross-validation with various validated and standardized in vivo, 
ex vivo and in vitro experimental data sets. ii) Most of the re-
ported models are derived for a tightly constrained applicability 
domain of pure and aqueous solutions, whereas such studies are 
in fact mainly needed for formulated products such as cosmet-
ics, pharmaceutical creams or plant protection productsm. iii) 
Reported models are not integrated with the systems biology of 
biophysical and biological events leading to the epithelia end-
points. iv) Most of the models, including the evolving molecular 
dynamic models, appear to be limited in their generalizability 
and applicability. Several studies have been reported recently to 
address the above issues. A number of limitations appear to be 
intrinsic to the approach however – for example, it is generally 
questionable if a simple (Q)SAR model would be able to reflect 
the multilayered process of dermal absorption of a compound 
applied in a complex formulation (Guth et al., 2014). Recent 
approaches focus on mechanistic modeling of the transport and 
disposition kinetics of chemical compounds in multilayered skin 
at the cellular level (Dancik et al., 2013; Kasting et al., 2013; 
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secretion of mucins that form an additional protective barrier), 
Paneth cells (secretion of antimicrobial peptides) and entero-en-
docrine cells (secretion of hormones regulating motility and re-
lease of digestive enzymes). Other important cell types present 
are involved in antigen processing and mucosal immunity, for 
example intraepithelial lymphocytes and microfold (M) cells, 
which transport organisms and particles from the gut lumen 
across the epithelial barrier to immune cells (Kucharzik et al., 
2000; Wittkopf et al., 2014). 
The epithelial cell layer not only provides a means for trans-
port, but also constitutes the first layer of protection against for-
eign material at the intestinal mucosal surface. The commensal 
microbiome also plays an important role in the structural, bar-
rier, immunological and metabolic functions of the intestine; 
however, a description of the microbiome at various mucosal 
surfaces is beyond the scope of this article (Brown et al., 2013; 
Rosenstiel, 2013). The junctions between the epithelial cells, 
tight and adherens junctions, which join cells to each other at the 
apical end of the lateral membrane (Schneeberger and Lynch, 
2004), play very important roles in the homeostasis of the in-
testine and the maintenance of mucosal immunity. Tight junc-
tions serve both as “gates” that seal the paracellular space and 
as diffusion “fences,” to maintain the apical/basolateral polarity 
essential to perform asymmetrical exchanges (Sambuy, 2009) 
and maintain epithelial cell polarity by preventing intermixing 
of plasma membrane proteins and restricting diffusion of lip-
ids in the exoplasmic membrane leaflet (Cereijido et al., 2008). 
These junction proteins also regulate epithelial cell prolifera-
tion and apoptosis. Furthermore, cell adhesion molecules are 
required in cell-cell and cell-matrix interactions, cell migration, 
cell cycle, and signaling. The epithelium is highly regenerative 
in nature, with reparative processes being driven by intestinal 
stem cells residing in the crypts of Lieberkuehn at the base of 
the villi (Clevers, 2013).
In drug discovery, knowledge of the absorption and metabo-
lism at the intestinal barrier is of particular importance, since 
the oral bioavailability of a compound is defined as the fraction 
of an oral dose that reaches the systemic circulation. Since the 
oral route remains the most popular route of administration of 
drugs worldwide, the prediction of the in vivo performance of a 
drug candidate after oral administration to humans is one of the 
major goals and challenges in the drug discovery industry today. 
Furthermore, oral absorption has come into focus in pharmaceu-
tical development in recent years, as new compounds tend to 
be larger and bulkier; their molecular weight and lipophilicity 
therefore increases, leading to both permeation and solubility 
issues. In general, intestinal absorption can occur via passive 
diffusion through the paracellular spaces and/or membranes of 
absorptive cells, vesicular uptake (endocytosis/pinocytosis), 
and release at the basolateral space (transcytosis). This trans-
port can be receptor- or transporter-mediated across the apical 
domain, with subsequent passive diffusion into the basolateral 
space. Each transport mechanism depends on the physicochem-
ical properties of the absorbed compound. In carrier-mediated 
events the drug molecule represents a substrate for (a) specific 
transporter(s) which localize(s) within the biological membrane 
(Kapitza et al., 2007). Carrier-driven translocation of trans-
and behavior (Arpaia et al., 2013; Foster and McVey Neufeld, 
2013; Hsiao et al., 2013; Possemiers et al., 2009; Tralau et al., 
2014). Yet, the microbial side of xenobiotic skin metabolism 
has so far not been addressed, and none of the aforementioned 
systems is fit to include the metabolic competence of the micro-
biome. A recent proof of principle study showed the formation 
of cytotoxic and carcinogenic metabolites from benzo[a]pyrene 
(B[a]P) by common skin commensals (Sowada et al., 2014; T. 
Tralau, personal communication). While it remains to be seen if 
and how this metabolism affects the human host, this example 
shows that it is necessary to further assess the influence of the 
microbiota and, concomitantly, the potential need for its inclu-
sion into toxicity testing. 
Having an understanding of both the possibilities and limita-
tions of the currently available skin models is very important. 
Where available and feasible, the use of ex vivo human skin or 
in vitro skin models should not be limited by lack of experi-
ence or distrust, especially if evidence exists that such models 
may provide similar or even better predictions than their ani-
mal-based counterparts. Well-designed validation studies with 
clearly defined goals, target levels for sensitivity and specificity 
and sets of reference compounds with reliable in vivo animal or 
human data for a particular area are therefore the most effective 
way to facilitate and implement the use of such novel methods. 
It has already been demonstrated by validation studies that 
for relatively simple toxicological endpoints, such as those em-
ployed for example for estimating the risk of skin corrosion 
or irritation for classification and labeling purposes, the use of 
relatively simple methods and models may suffice. However, 
for more complex endpoints such as skin sensitization or in in-
vestigation of a skin disease therapy, more complex models are 
required, and other approaches will be needed, combining suit-
able methods and tools into respective testing strategies. Novel 
biomarkers will also have to be investigated and incorporated 
into the researcher’s toolbox. 
3  Non-animal models of the intestinal  
mucosa in research, industrial applications  
and regulatory toxicology
3.1  General introduction
The gastrointestinal tract has a number of physiological func-
tions including digestion, absorption, hormone and enzyme 
release, peristalsis, antigen presentation, control of microbial 
growth, and excretion. These vital functions are maintained 
by a diverse set of cell types and a unique tissue architecture. 
The intestinal mucosa is characterized by the presence of villi, 
which constitute the anatomical and functional unit for nutri-
ent and drug absorption, and can be further subdivided into the 
epithelial layer (which constitutes the intestinal barrier), the 
lamina propria (collagen matrix containing blood and lymphatic 
vessels) and the muscularis mucosae (Carr et al., 1981; Hoso-
yamada and Sakai, 2005; Nelson, 2004). The intestinal epithe-
lium is mostly made up of absorptive enterocytes that transport 
macromolecules, ions and water. Secretory cell types within the 
epithelium include goblet cells (which are responsible for the 
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absorption models continues to lie in the development and regu-
lation of drug products. However, currently available models 
also appear interesting for the “animal-free” evaluation of many 
non-pharmaceutical products, such as dietary supplements, 
plant protection products, biocides or other chemicals, as well 
as nanomaterials. Physiology-based pharmacokinetic (PBPK) 
modeling is gaining importance as an alternative to animal stud-
ies for risk assessment and toxicology in general, setting the 
stage for in-depth evaluation of underlying mechanisms as well 
as factors of pathogenicity on a molecular and cellular level. 
Experimental model systems which are able to accurately pro-
vide toxicity assessment as well as a correlation between altered 
permeability and absorption and immunotoxicity are however a 
continuing and urgent need. 
3.2  Ex vivo intestine models
Ex vivo intestinal cultures are important models for analyzing 
and assessing drug transport, cell-cell communication, safety 
aspects, and other interactions of orally consumed exogenous 
substances or pathogens in a three-dimensional tissue context 
of the gastrointestinal tract. Most substances first come into 
contact not with the epithelial cells themselves, but rather with 
mucus on the epithelial mucosa (Macierzanka et al., 2014). The 
mode of interaction with the biological barrier depends on the 
nature of the substance (i.e., particulate or soluble) – generally 
particulate substances cross the epithelial barrier via M cells 
or dendritic cells leading to accumulation in Peyer’s patches 
(Brun et al., 2014; Schimpel et al., 2014). The gastrointestinal 
microbiota must also be considered in this respect as it plays 
an important role in the overall interaction and metabolism of 
orally consumed substances. As the gut is a highly organized 
and complex organ, it is challenging to maintain gut properties 
in an ex vivo situation for prolonged periods of time – changes 
may occur rapidly due to a lack of intact vascularization and 
nutrient supply. Lack of vascularization in particular quickly 
results in hypoxia, necrosis, loss of viability and subsequently 
functionality. Previously, freshly excised and perfused whole 
intestinal segments were used, obtained in the majority of cases 
from mice, rats or piglets. Whole organ segments or organo-
typic cultures can be maintained either as a free-floating cul-
ture or on a culture substratum in vitro (Jacobs-Cohen et al., 
1987; Metzger et al., 2007; Quinlan et al., 2006; Rothman and 
Gershon, 1982). These segments have the advantage that physi-
ological cell-cell contact and normal extracellular matrices are 
preserved, at least for a limited time. Most studies to date have 
however been restricted to fetal gut tissues and relatively short 
culture duration. When using the slice culture technique, main-
tenance of the three-dimensional environment of the fetal gut 
could be extended up to several weeks in vitro (Metzger et al., 
2007). This offers the possibility for experimental manipulation 
and monitoring in long-term studies. Only a few groups have 
worked with adult intestinal tissue (Autrup et al., 1978a,b; De-
fries and Franks, 1977; Finney et al., 1986; Metzger et al., 2009; 
Moorghen et al., 1996; Shamsuddin et al., 1978). In this case, 
several biopsy punches can be obtained from the same intestinal 
tissue, placed in a Transwell® setup with nutritive media, and 
incubated with the test material. Besides transport activity, the 
porter substrates may be a passive occurrence, dependent on the 
existence of a concentration gradient, and results in either cel-
lular uptake or efflux out of the cell. As this process is saturable, 
in the case of drugs showing low passive permeability, carrier 
saturation will give rise to a marked alteration in the absorbed 
fraction (Buckley et al., 2012). In addition, several carrier-me-
diated transport processes are coupled to a primary or secondary 
energy source (e.g., multidrug efflux pumps as primary active 
transport proteins), able to transport their substrates against con-
centration gradients (Buckley et al., 2012). 
Besides knowledge about individual drug transport across the 
intestinal barrier, provision of toxicokinetic data is mandatory in 
pre-clinical drug development. To this end, animal experiments 
have a long tradition of use for pre-clinical risk assessment of 
new drugs. Similarly, in vivo toxicokinetic studies according to 
OECD test guideline 417 are part of data requirements for some 
sectorial chemicals regulations, such as those for plant protection 
products (Regulation (EC) No. 1107/2009) and biocides (Regu-
lation (EU) 528/2012). An overview of regulatory provisions 
on ADME (absorption, distribution, metabolism and excretion) 
and toxicokinetics is available in the recently published EURL 
ECVAM (European Reference Laboratory for Alternatives to 
Animal Testing) strategy for achievement of 3Rs impact in the 
assessment of toxicokinetics and systemic toxicity (Bessems 
et al., 2015). However, it becomes more and more evident that 
animal-derived pharmaco-/toxicokinetic data are not always re-
liable for extrapolation to human safety assessment due to inter-
species differences in physiology as well as in biochemical and 
metabolic pathways. Low-throughput, high costs and ethical 
considerations are further limitations associated with the use of 
animals (see also requirements in EU Directive 2010/63/EU on 
the protection of animals used for scientific purposes (Martinez, 
2011)). To reduce animal experimentation and also the risk of 
failure of many drug candidates in the later phases of clinical 
trials, attempts have been made to provide inexpensive and con-
venient intestinal functional ex vivo and in vitro models to study 
toxicity and bioavailability of new substances and to study in-
teractions between the host, pathogens and intestinal microflora. 
Advances have also been made in artificial membrane technol-
ogy and in silico modeling systems, which may complement 
the cell/tissue models. An essential part of developing non-
animal models is their validation, together with demonstration 
that their use provides equally viable (or even better) results 
in comparison to animal tests. Therefore, several national and 
international institutions like EURL ECVAM in the EU, the US 
validation body, the National Toxicology Program Interagency 
Center for the Evaluation of Alternative Toxicological Methods 
(NICEATM) and the Interagency Coordinating Committee on 
the Validation of Alternative Methods (ICCVAM), the Japanese 
Center for the Validation of Alternative Methods (JaCVAM) or 
the Organization for Economic Co-operation and Development 
(OECD) validate and keep track of new models (Hartung et al., 
2004; Leist et al., 2012). 
Overall, functional non-animal intestinal models play an 
increasing role in predicting and evaluating pharmacokinetic 
properties (in particular, oral bioavailability). The incentive for 
initial investigation as well as current application of intestinal 
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In general, species-specific differences must be considered if 
data obtained from such models are translated to humans. The 
properties and, in particular, the dissolution properties of biop-
harmaceutical compounds themselves must also be considered 
as these also have a strong influence on the ability to establish 
an in vivo-in vitro correlation (IVIVC). Drugs belonging to 
class I of the Biopharmaceutics Classification System (BCS) 
can generally be expected to exhibit a good IVIVC, as they are 
both highly soluble and permeable; an IVIVC could also be ex-
pected for BCS class II drugs as dissolution is the rate limiting 
step in the absorption of such poorly soluble but highly perme-
able drugs. In contrast, for BCS class III (high solubility, poor 
permeability) and class IV (poor solubility, poor permeability) 
drugs, an IVIVC is generally unlikely (Lu et al., 2011). It must 
also be kept in mind that establishing a regular supply of freshly 
excised animal tissue still imposes logistical challenges to the 
implementation of such models for medium- to high-throughput 
applications in an industrial context. 
3.3  Reconstructed human intestinal  
models in vitro
3.3.1  Cell lines (standardization and validation)
Immortalized human adenocarcinoma cell lines such as Caco-2 
or T84 (Khare et al., 2009; Raffatellu et al., 2005; Tran et al., 
2010; Khare et al., 2012) have been extensively used to study 
absorption mechanisms, as such cell lines have been shown to 
act as acceptable models for the investigation of enterocyte dif-
ferentiation and function (Cencič and Langerholc, 2010). Cells 
are commonly grown on semi-permeable Transwell® inserts, 
where they form a polarized monolayer and exhibit villi for-
mation. Earlier studies have shown that Caco-2 and T84 cells 
spontaneously express differentiation characteristics of mature 
enterocytes by forming a polarized monolayer with an apical 
brush border, tight junctions and the presence of brush border-
associated hydrolases (Bolte et al., 1998). However, the Caco-2 
cell line in particular is heterogeneous and highly dependent on 
culture conditions, leading to variable transport properties and 
permeability (Delie and Rubas, 1997; Hosoya et al., 1996; Va-
chon and Beaulieu, 1992). Caco-2 cells are cultured on porous 
filter supports until fully differentiated and polarized, as denoted 
by a TEER in excess of 300 Ω cm2 (van Breemen and Li, 2005), 
although lower values have also been reported (Buckley et al., 
2012). Caco-2 TC7, a clone isolated from a late passage of the 
parental Caco-2 line, is as reliable a model for passive diffusion 
as the parental cell line; however it seems not to be predict-
able for intestinal absorption of highly lipophilic compounds 
and poorly absorbed compounds, or when transporter-mediated 
routes and/or first pass metabolism are involved (Turco et al., 
2011). As the absorption of xenobiotics is not only restricted to 
passive diffusion, the expression of active transport and efflux 
systems (such as P-glycoprotein) in employed cell lines is cer-
tainly important (Yang, 2013). 
When compared, it is evident that there are some significant 
differences between polarized Caco-2 and T84 cells. For in-
stance, Caco-2 cell monolayers exhibit significantly lower TEER 
on confluence as compared to T84 cells. Decreases in TEER are 
end points measurable in such a test system include changes in 
the histopathological assessment, as well as changes in the ex-
pression of genes at transcription or translation level.
More recently, whole jejunal gut segments from adult rats 
and 6 week old pigs with intact arterial and venous vessels 
could be maintained on a histological level for up to 2 weeks in 
specially constructed computer-assisted bioreactors and adapt-
ed medium conditions (H. Walles, unpublished data). If drugs 
were administered into the lumen, epithelial transport could be 
measured directly in the vessel circulation, which would pro-
vide a physiologically-accurate approach. Therefore, these ad-
vanced models could be useful in later phases of pre-clinical 
development and provide additional insights into drug absorp-
tion and metabolism processes.
For short duration drug absorption studies so far the most 
common applications of ex vivo gut cultures are the Ussing 
chamber and the (non-)everted gut sac model. Ussing cham-
bers were introduced by Ussing and Zehran in 1951 for study-
ing the active transport of sodium as a source of electric current 
in short-circuited, isolated frog skin. The usefulness of Ussing 
chambers for intestinal transport and barrier studies has also 
long been recognized. The chamber consists of an apical (mu-
cosal) and basolateral (serosal) compartment separated by the 
mucosal/submucosal tissue, with the possibility for drug expo-
sure at either side. The chambers are filled with physiological 
electrolyte solution, which is gas- and temperature-controlled. 
The simplicity of Ussing chambers makes them an attractive 
ex vivo model system for studying drug transport (Brun et al., 
2014; Schimpel et al., 2014; Shah and Khan, 2004). When 
properly equipped with electrodes, effects of compounds on 
electro-physiological parameters of the intestinal barrier can 
be determined, which may provide additional information on 
the pharmacological behavior of the test compound (Shah and 
Khan, 2004).
The everted gut sac (mostly of rat) small intestine can be used 
to study drug transport across the intestine and into epithelial 
cells, and to determine kinetic parameters with high reliability 
and reproducibility. Integrity of the model can be monitored via 
measurement of transepithelial electrical resistance (TEER) and 
reference substances (Brun et al., 2014; Schimpel et al., 2014). 
A defined length of gut lumen is filled with test substances and 
closed at both ends. Oxygenated tissue culture media ensures 
tissue viability for up to 2 hours. Usually, sensitive detection 
methods are needed and therefore radiolabeled compounds 
are most appropriate and used in this approach. The gut sac 
model is suitable for measuring absorption at different sites of 
the intestine and is useful for estimating the first-pass metabo-
lism of drugs in intestinal epithelial cells. In the past, mostly 
macromolecules and liposomes were studied; more recently 
the paracellular transport of hydrophilic molecules and the ef-
fect of potent enhancers has also been investigated (Feng et al., 
2013; Neupane et al., 2013). A limitation of this model is that it 
does not reflect the actual intestinal barrier, as compounds pass 
from the lumen into the lamina propria and across the muscu-
laris mucosa, which is usually not removed from everted sac 
preparations (Freag et al., 2013). Thus, transport of compounds 
might be underestimated. 
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system failed to represent the characteristic crypt-villus mor-
phology of the adult epithelium (Ootani et al., 2009). 
More recently, several independent groups published excit-
ing novel culture protocols allowing the long-term culture of 
primary intestinal epithelial cells in vitro as intestinal organoid 
structures (Jabaji et al., 2013; Sato et al., 2009). In this respect, 
mouse and human intestinal crypts are embedded in a three di-
mensional matrix such as Matrigel or Collagen I covered with 
medium basically mimicking the intestinal stem cell niche by 
providing factors of the Wnt-, EGF-, BMP-, and Notch-signal-
ing pathways (Cao et al., 2013; Farin et al., 2012). Over several 
days crypt cells form spherical structures with a crypt-like lu-
men, referred to as human enterospheres. Small intestine and 
colon spheres can expand into multilobulated enteroids that 
mimic the ordered structure of the epithelium including crypts 
containing multipotent columnar base stem cells and Paneth 
cells. The remaining cell types such as enterocytes, goblet cells 
and enteroendocrine cells can be observed in larger cysts away 
from the crypt compartment. In these cysts, proliferation signals 
are down-regulated while differentiation is induced (Reynolds 
et al., 2014). For further promotion of differentiation into secre-
tory lineages, Notch signaling can be reduced by γ-secretase in-
hibitors (such as DAPT) and omission of Wnt3A (Milano et al., 
2004). Success and yield of the human culture protocol strongly 
depends on the donor tissue including age, gut region and pa-
thology. While three-dimensional organoids derived from pri-
mary intestinal cells appear to possess physiologically relevant 
phenotypes, they cannot be used to assess classical functionality 
typically determined within 2-dimensional Transwell® cultures, 
such as the formation of monolayers with tight junctions and 
intestinal permeability and transport. However, through devel-
opment of a real-time imaging system and mathematical mod-
eling, the organoid system has been utilized as an efficient tool 
to evaluate the dynamics of P-gp efflux transporter-mediated 
drug transport (Mizutani et al., 2012).
3.3.3  Stem cell-derived intestinal cells 
Stem cells have the capacity to self-renew and differentiate 
into the various cell lineages that build specific tissue types. In 
particular, multipotent intestinal stem cells have an enormous 
regeneration potential and are responsible for continuous self-
renewal of the gut epithelium in vivo. Recently, based on the 
three-dimensional organoid protocols described above, several 
groups have independently published descriptions of methods 
by which leucine-rich repeat-containing G protein-coupled re-
ceptor 5 (LGR-5)- or Ephrin type-B receptor 2 (EphB2)-posi-
tive intestinal stem cells can be isolated from primary murine 
or human intestinal tissue and efficiently grown as organoids in 
vitro (Jung et al., 2011; Sato et al., 2009). Concerning the crypt 
culture protocol, flow cytometry-purified intestinal stem cells 
can be embedded in Matrigel™ and maintained in growth fac-
tor-enriched medium, the composition of which varies slightly 
depending on the gut region and species. Currently, the employ-
ment of Matrigel™ seems absolutely essential as it provides a 
three-dimensional laminin- and collagen-rich matrix mimicking 
the basal lamina. After organoid formation, new cells are contin-
uously generated at the bottom of the crypt-like compartments, 
accompanied by an increase in the permeability of intestinal epi-
thelial cells, and as such, variations in TEER have been used as 
an indicator of early sub-lethal epithelial toxicity (Ferruzza et al., 
1999; McCall et al., 2009). There are also marked differences 
in Na+-dependent nucleoside transport systems in T84 cells as 
compared to Caco-2 cells (Ward and Tse, 1999). Furthermore, 
T84 cells produce mucin in culture and thus more closely mimic 
the intestinal surface (McCool et al., 1990); they also respond to 
external stimuli to exert innate immune responses similar to those 
initiated at the intestinal luminal surface (Ou et al., 2009). 
Several endpoints are utilized to evaluate the performance of 
intestinal system bio-barrier function. Some of these include the 
aforementioned TEER, increases in the permeability of epithe-
lial cells, changes in gene expression of cell junction proteins 
(gap junctions, adherens junctions and tight junctions), immu-
notoxicology, and cell proliferation. Typically, specific compo-
nents of seeded cell lines used to evaluate model function are 
apical and basal supernatants as well as cell lysates, which are 
used to monitor signaling molecules, activation factors, com-
pound concentrations and numerous other parameters. While 
immortalized cells offer many advantages, extrapolation of data 
generated with these cell lines to in vivo conditions is often dif-
ficult, as such cells originate from tumors and may therefore 
not be representative of the true physiological environment (Le 
Ferrec et al., 2001). 
3.3.2  Primary intestinal cells
Due to limitations of immortalized intestinal cell lines, many 
studies have focused on the use of primary intestinal epithelial 
cells as a more physiologically relevant cell-based approach 
(Aldhous et al., 2001; Booth et al., 1999; Pageot et al., 2000; 
Perreault and Beaulieu, 1998; Simon-Assmann et al., 2007). 
However, while isolated human intestinal epithelial cells in 
particular retain important in vivo anatomical and biochemical 
features, they are difficult to culture and have limited viability. 
As a result, until recently, no well-defined, robust culture sys-
tem had been identified and long-term propagation of native, 
non-transformed primary cells from the intestine was not feasi-
ble. In most culture systems intestinal cells transiently divided, 
yet ceased proliferation after several days and finally under-
went apoptosis. In the early stages of culture, these primary 
cells had the capacity to form monolayers with tight junctions 
and expressed general epithelial markers, such as cytokeratins 
8 and 18 (Bosch et al., 1988); however, little characterization 
had been performed regarding their expression of intestinal cell 
type-specific markers or transport function. It was generally 
assumed that it would not be possible to establish long-term 
cultures of primary adult tissues without the introduction of ge-
netic transformations promoting cell proliferation and survival. 
In 2009 however, Ootani et al. published details of an in vitro 
culture system that facilitated the long-term propagation (for 
several months) of intestinal fragments containing epithelial 
and mesenchymal cells from neonatal mice in a collagen gel 
with air interface supplemented with serum. Such cultured in-
testinal cells grew out into cystic structures, forming a simple 
epithelium comprising all major intestinal cell types associated 
with an underlying myofibroblast layer. However, this culture 
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ing other important cell types such as vascular endothelial cells 
and neural cells from hiPSCs (Lee et al., 2007; Levenberg et 
al., 2002), it should also be possible to incorporate vascular and 
neural networks.
3.3.4  Co-culture and pathophysiological models 
The intestine exists in a fine balance of endogenous and exog-
enous factors provided by multiple cells in the mucosal niche. 
If this tightly regulated system is disturbed, inflammation, in-
fection or cancer may result. Therefore, single cell based as-
says to mimic the intestinal system are overly simplified and in 
most cases do not adequately represent the complex interplay 
between the different cell types under pathological conditions. 
Adding further important cell types to generate advanced 
three-dimensional co-culture models may help to improve the 
features of intestinal model systems or to better understand 
pathological symptoms. Within the intestinal stem cell niche, 
signals to maintain the undifferentiated nature of these cells, 
and thereby the epithelial integrity, are provided by surrounding 
mesenchymal cells. The alpha-smooth muscle actin expressing 
intestinal subepithelial myofibroblasts (ISEMFs) are known to 
support long-term epithelial growth in vitro and wound healing, 
for instance (Lahar et al., 2011; Seltana et al., 2010). This effect 
may be caused by factors such as R-Spondin-2, a Wnt-agonist, 
but it is still unclear if cell-cell contacts are necessary (Lei et al., 
2014). More research is needed to understand the complex in-
terplay between the different cell types to maintain the intestinal 
stem cell niche and gut homeostasis.
A number of investigations have been carried out previously 
to explore the use of co-culture systems in permeability stud-
ies (Walter et al., 1996; Wikman-Larhed and Artursson, 1995). 
From a commercial viewpoint, the small intestinal (SMI) tissue 
model available from MatTek exhibits more physiologically rel-
evant TEER values as compared to conventional Caco-2 mono-
cultures (Ayehunie et al., 2014; Maschmeyer et al., 2015a) and 
allows for conduction of relatively long-term (up to 4 weeks) 
permeability studies. The SMI model is also suitable for inves-
tigation of compound metabolism and toxicity in healthy situ-
ations, as well as in simulated acute and chronic conditions of 
inflammation and potentially also infection. Indeed, there is an 
increasing need for pathological models in addition to “healthy” 
gut modelling. Chronic inflammatory bowel diseases (IBD) 
such as ulcerative colitis and Crohn’s disease have an increas-
ing incidence within industrial countries. The treatment options, 
however are still rather symptomatic than curative. Therefore, 
recently developed co-culture models involving cells of the im-
mune system like monocytes, macrophages or dendritic cells 
could aid in understanding the role of certain cell types in these 
diseases, and in the development of novel treatment strategies 
(Leonard et al., 2010, 2012; Spottl et al., 2006). Similarly, au-
tologous, humanized primary co-culture models (H. Walles lab, 
unpublished data) constitute a further improvement for the de-
velopment and testing of new vaccines for more efficient and 
individualized treatment of gastrointestinal cancers, which 
show an extremely high prevalence worldwide. Finally, severe 
infections can disturb the tight balance of the microbiota lead-
ing to symptoms such as inflammation, dysmotility or even can-
where they proliferate, differentiate and are shed into the central 
cyst lumen some days later. Such organoids can be propagated 
for several months without significant changes of phenotype 
and karyotype. The culture protocol has also be demonstrated 
to be successful when employed with single stem cells in cell 
cloning experiments, although with less efficiency as important 
factors from crypt niche cells such as the Paneth cells are miss-
ing. Overall, the homeostasis of the generated organoids faith-
fully represents the in vivo situation and can be used for toxic-
ity studies or, to some extent, also to study dynamics of drug 
transport in a three-dimensional tissue environment. However, 
the ability to grow enteroids as polarized monolayers instead 
of spheroids and without Matrigel™ would be advantageous, 
as this would permit direct and undisturbed apical exposure of 
compounds in transport studies. It is noteworthy in this case that 
enteroids contain only epithelial cell types, and do not represent 
additional cell and tissue types such as smooth muscle, support-
ing fibroblasts, endothelial cells, or enteric nerves.
Generation of more biologically-complex intestinal tissue 
has been accomplished through directed differentiation of (em-
bryonic or induced) pluripotent stem cells to intestinal tissue 
(Kauffman et al., 2013; Ogaki et al., 2013). In general, pluripo-
tent stem cells can be differentiated into all cells of the three 
embryonic germ layers. In particular, embryonic intestinal de-
velopment can be mimicked by application of a temporal series 
of growth and differentiation factors. The process is initiated 
using the Nodal-related protein Activin-A, which directs dif-
ferentiation of pluripotent stem cells into definitive endoderm 
up to 90% purity according to Sox17 and FoxA2 expression 
(D’Amour et al., 2005). Further, synergistic activation of the 
fibroblast growth factor and Wnt signaling pathways has then 
been used to promote formation of a posterior gut tube and pro-
mote growth of the intestinal mesenchyme. Intestinal cultures 
were then propagated under similar conditions as described for 
the organoid cultures under Matrigel™ conditions (Spence et al., 
2011). The epithelium contained crypt and villus-like structures 
as well as all of the cell types normally found in the gut. Gene 
expression included caudal type homeobox2 (CDX2, a hindgut 
marker), E-cadherin (cell-to-cell junction marker), and Villin 
(epithelial brush border marker). The enclosed mesenchyme 
expressed markers for smooth muscle cells, myofibroblasts 
and fibroblasts. The organoids showed basic intestinal function 
including absorption of amino acids and secretion of mucus, 
and were able to be passaged for several months (reviewed by 
Finkbeiner and Spence, 2013), although cells were rather imma-
ture compared to fully differentiated epithelial cells. As for the 
adult stem cell-derived organoids, functional transport studies 
of drugs across epithelial monolayers using established Tran-
swell® systems has not been demonstrated to date.
Nevertheless, pluripotent stem cells provide a promising de-
fined and unlimited cell source for intestinal model generation 
and regenerative medicine. Furthermore, the recent progress 
of technologies utilizing human induced pluripotent stem cells 
(hiPSCs) may provide a valuable tool for oral drug discovery, as 
patient-specific somatic cells can be reprogrammed and directly 
differentiated to intestinal tissue for more physiologically rel-
evant disease modeling. Given that protocols exist for generat-
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ible and useful for early-stage ADME screening, posing a low-
cost and high-throughput non-cellular methodology. PAMPA 
models with different lipid compositions have been established; 
for instance models may consist of a single lipid such as leci-
thin (Kansy et al., 1998) or mixtures of phosphatidyl-choline, 
-ethanolamine, -serine, -inositol and cholesterol (biomimetic 
PAMPA, Sugano et al., 2003). A 20% dodecane solution of a 
phospholipid mixture (Avdeef et al., 2005), silicone oil and iso-
propyl myristate (Ottaviani et al., 2006) – which does not occur 
in vivo – systems of lipid bilayers (Nirasay et al., 2011), and also 
lipid triple-layers (Chen et al., 2008b) as well as synthetically 
generated amphiphilic phospholipids (Yu et al., 2015) also ex-
ist. An interesting example of a comparison between cell-based 
and artificial membrane assays was published by Kerns et al. 
(2004), where permeability data from Caco-2 cell monolayer 
and PAMPA methods was compared. This work showed a cor-
relation between passive permeation as determined by the two 
models. Compounds which deviated from this correlation fell 
into two clear categories – compounds which were known to be 
subjected to absorptive transport mechanisms (associated with 
active transport, paracellular permeation, and gradient passive 
diffusion) and compounds known to be affected by secretory 
transport (related to efflux and gradient passive diffusion). Such 
a combination of assays as employed in the study in question 
presents an interesting approach to enable differentiation be-
tween permeation mechanisms.
3.6  In silico modeling
One of the earliest (if not the earliest) computer models used to 
describe intestinal absorption was an analog computer circuit 
for differential equations detailing a variable rate of glucose ab-
sorption from the intestine, taking into account the feedback ef-
fects of blood glucose levels and insulin production (Janes and 
Osburn, 1965). Not long after, many pharmaceutical scientists 
began using computer modeling to model biopharmaceutical 
and pharmacokinetic processes (Beckett and Tucker, 1968), in-
cluding the kinetics of buccal absorption (Beckett and Pickup, 
1975), as well as to solve intractable or difficult pharmacoki-
netic analysis of advanced models for oral absorption (Wagner, 
1975). Later analyses included computer modeling of transport 
processes across human gastrointestinal epithelia, including the 
presence of an aqueous diffusion layer and saturable transport 
in the human jejunum (Read et al., 1977) and numerical simu-
lation of differential equations describing absorption processes 
along the length of the intestine (Atkins, 1980). The principles 
applied in these studies then evolved to include digital comput-
ing and deconvolution methodology to assess gastric and intes-
tinal absorption (Veng-Pedersen, 1987). A key step forward in 
this respect was the numerical analysis of transport in and from 
the intestine represented as a nonlinear, multi-compartment 
mixing tank model based on human physiological parameters 
(Luner and Amidon, 1993). This model is the forerunner to the 
now widely used computer program GastroPlus® (see below). 
At approximately the same time, simulations on the non-linear 
behavior of controlled products and the absorption of their con-
tained actives along the length of the intestine were developed 
(Grass et al., 1994). 
cer. Currently, a clear limitation in studying human pathogens 
is the availability of relevant humanized infection models. This 
is particularly true for obligate human pathogens (e.g., Salmo-
nella, Helicobacter pylori and Campylobacter jejuni) for which 
no animal reservoir is known (Dostal et al., 2014; Höner zu 
Bentrup et al., 2006; Naughton et al., 2013). Since simple cell 
culture systems and also animals are highly artificial models for 
obligate human pathogens, novel human infection models based 
on engineered human tissue are needed and are in fact currently 
under development (unpublished data).
3.4  Chip technology
Several new biological models mimicking the organ-organ in-
teractions between the intestine and the liver have recently been 
developed, using coupled polycarbonate cell culture inserts and 
microfluidic biochips in integrated fluidic platforms which al-
lows for the performance of dynamic co-cultures. In one such 
system, the Integrated Insert in a Dynamic Microfluidic Plat-
form (IIDMP), the intestinal compartment is simulated using 
Caco-2 TC7 cells, while the hepatic component is represented 
by HepG2C3A cells (Bricks et al., 2014). Another novel multi-
organ chip model (MOC, TissUse) utilizes primary small in-
testinal epithelial cells (SMI-100, MatTek) and HepaRG liver 
spheroids to reproduce intestine liver interactions (Maschmeyer 
et al., 2015a,b; Materne et al., 2015). Additionally, a “Gut-on-
a-Chip” has been recently developed using Caco-2 cells (Kim 
and Ingber, 2013). In such a setup, cells are cultured within 
micro-fluidic channels of a clear, flexible, polydimethylsiloxane 
(PDMS) device created with microchip manufacturing that per-
mits application of fluid flow as well as cyclic mechanical strain 
at levels similar to those experienced by epithelial cells in living 
intestine (Kim et al., 2012).
3.5  Synthetic membrane systems
Artificial membranes represent attractive alternatives to the 
use of models employing native tissue. Such models may be 
highly predictive of in vivo conditions, are capable of express-
ing and allowing for the investigation of drug transport systems, 
and may also be relatively cost-efficient (Buckley et al., 2012). 
Artificial membrane technology is generally used to measure 
passive permeation through membranes composed of mixtures 
of phospholipids in dodecane, supported by an inert polycar-
bonate filter membrane, such as in the case of the Parallel Ar-
tificial Membrane Permeability Assay (PAMPA) (Avdeef et al., 
2004; Kansy et al., 1998), or through lipid layers consisting of 
sedimented liposomes supported by filter membranes, as in the 
Phospholipid Vesicle-Based Permeation Assay (PVPA) (Fischer 
et al., 2011; Flaten et al., 2006a,b, 2007; Kanzer et al., 2010). 
PAMPA assays estimate the passive transcellular permeability 
(Buckley et al., 2012) of compounds from one compartment (do-
nor microtitre plate) to another, overlying compartment (mem-
brane acceptor), through an artificial porous membrane infused 
with biobarrier constituents and lipid solutions. The amount of 
a compound which diffuses into the acceptor compartment pro-
vides an indication of its passive penetration ability. As only 
approximately 5% of all drugs are estimated to be taken up via 
active transport (Artursson, 1998), PAMPA approaches are cred-
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established based on statistical models including multiple linear 
regression, partial least squares, linear discriminant analysis, ge-
netic algorithms and support vector machines (Hou et al., 2006). 
Many computational models deal with the prediction of intesti-
nal drug absorption and aim to identify important physicochemi-
cal properties in order to improve absorption of the investigated 
compounds (Hamalainen and Frostell-Karlsson, 2004). 
Data analysis is often based on the assumption of a single per-
meation barrier separating donor and receiver compartment and 
simple diffusion according to the spatial gradient (Fick’s first 
law). The application of such single barrier models can be an 
over-simplification of the cell monolayer however. Refinements 
include different active and passive absorption routes, and vari-
ation of pH as well as enzyme and transporter expression levels 
in order to improve the model of the absorption along the intes-
tine (Heikkinen et al., 2010). Single barrier models are helpful 
for the basic analysis of concentration-independent mechanisms. 
More complex compartmental models have been developed for 
the simulation of intestinal transit, which describe the transfer 
of a compound between several kinetic compartments. Also, the 
cell monolayer can be subdivided by this approach into several 
compartments (Zhang et al., 2006). These mathematical models 
define the rates of compound movement by differential or other 
algebraic equations. If these equations are not analytically solv-
able, numerical methods have to be applied which require a high 
amount of computing power (Heikkinen et al., 2010). An exam-
ple of a commercially available software package used for such 
modeling is GastroPlus®, which is a whole body model integrat-
ing compound distribution, metabolism and pharmacodynam-
ics (http://www.simulations-plus.com/) utilized by a number 
of top pharmaceutical companies as well as various independ-
ent researchers (Heikkinen et al., 2012; Saxena et al., 2015). 
In contrast, the software Simcyp® simulates pharmacokinetic 
profiles and focuses on metabolic pathways of the cytochrome 
P450 enzymes (http://www.simcyp.com/). Combination of the 
Simcyp® population-based PBPK modeling platform with an 
intestinal pharmacokinetic model has also been utilized in order 
to take into account population variability, an area which is be-
ing increasingly emphasized (Hens et al., 2014). 
Perhaps the most definitive outcome from the in silico mod-
eling of intestinal transport has been the evolution of the afore-
mentioned BCS, now being used to classify which generic drugs 
need to undergo in vivo bioequivalence studies and to provide 
accurate IVIVC predictions (Tsume et al., 2014). However, in 
spite of this achievement, as well as the various developments 
detailed above, it also needs to be noted that we are a long way 
from precise prediction of human bioavailability. Several ex-
amples are available of instances where in silico and in vitro 
predictive models based on Caco-2 permeability measurements 
do not correlate with human intestinal permeability (Larregieu 
and Benet, 2013).
3.7  Conclusion 
Ex vivo, in vitro and in silico methods for oral drug toxicity and 
transport studies are available, as presented above and also sum-
marized in Table 3. They differ with regard to expense, com-
plexity, explanatory power, accuracy, etc., and are as such not 
Modeling of solute structural determinants of intestinal pen-
etration also represents a distinct phase in the development of 
in silico modeling. Studies carried out in this area utilized tech-
niques such as dynamics simulations of the polar surface area 
of prodrug and drug conformations to correlate to Caco-2 cell 
apparent permeability coefficients (Krarup et al., 1998), and 
quantitative structure-property relationships as an alternative to 
experiments in estimating the percent human intestinal absorp-
tion (Wessel et al., 1998). These developments have led to in 
silico modeling that uses a combination of solute physicochemi-
cal properties (such as lipophilicity, polarity, polarizability and 
hydrogen bonding) and statistical analysis to predict intestinal 
penetration (Norinder et al., 1999).
In the current environment we see a continuation of concepts 
developed in early in silico modeling of intestinal absorption, 
however using more sophisticated computation and advanced 
modeling. Such in silico models can decipher complex, highly 
variable absorption and food interaction pharmacokinetics for a 
modified release drug product using an object- and agent-oriented 
discrete event system, which maps various physiological features 
and processes (Kim et al., 2014). The current-day pharmaceutical 
industry has a huge financial interest in the inclusion of computa-
tional (in silico) analysis in early stages of drug screening. Such in 
silico approaches support the development of tailored drugs that 
are optimized to overcome the intestinal barrier; for this reason in 
silico models concentrate on the prediction of adsorption, distri-
bution, metabolism, excretion and toxicity (ADMET), properties 
of drug candidates which may be used to filter out substances 
that are unsuitable for further development and so minimize fail-
ure rates during drug candidate development and testing in fur-
ther screening studies and clinical trials (Wang and Hou, 2015). 
Furthermore, the creation of “drug-like”-compound libraries was 
initiated over ten years ago in order to improve efficiency in drug 
development. Besides ADMET criteria, these libraries should in-
corporate medicinal chemistry knowledge as well as information 
about structure and metabolic stability (Matter et al., 2001). For 
classification neural networks are often used that are trained on 
a set of substances with known characteristics. After the training 
step the neural networks are used to predict the properties of new 
compounds (Guerra et al., 2010). With a well-trained network and 
enough training data, “Lipinski’s rule of five” for optimal drug 
properties (which states that for oral activity, a drug should have 
≤ 5 hydrogen bond donors, ≤ 10 hydrogen bond acceptors, a mo-
lecular weight of ≤ 500 daltons, and maximum logP value of 5) can 
thus be extended to any desired set of properties and substances 
(van de Waterbeemd and Gifford, 2003). Proteins are in several 
aspects the drug candidates of choice as they exhibit desired char-
acteristics such as high selectivity and good response rates upon 
treatment, while causing fewer side effects (Antunes et al., 2013). 
In order to select intestinal barrier-permeable peptides from large 
peptide libraries, artificial neural networks have been applied 
to develop first models for prediction of intestinal permeability 
on the basis of peptide sequences (Jung et al., 2007). However, 
problems associated with proteins include their instability, high 
molecular weight and high hydrophilic character, which result in 
low permeability through biological membranes (Antunes et al., 
2013). For passive permeation several in silico models have been 
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Tab. 3: Models for intestinal absorption
Intestinal  
tissue
 
Cell-based 
systems
Artificial 
surrogates
In silico models
Intestinal explant  
(ex vivo)
Caco-2 monolayer 
(e.g., CacoReady, 
Advancell)
t84 polarized cells
GIt-PAMPA (Pion)
– Matter et al., 
2001
– Guerra et al., 
2010
– Jung et al., 2007
– Hou et al., 2006
– Hamalainen and 
Frostell-Karlsson, 
2004
– Heikkinen et al., 
2010
– mimics in vivo 
intestinal tissue
– full architecture of the 
intestinal mucosa and 
submucosa is present
– multiple biopsy 
punches can be 
taken from one tissue 
samples
– easily accessible
– regulatory 
acceptance for BCS 
classification
– reproducible
– metabolically 
competent
– information on active 
transport
– Papp useful for PBPK 
or bioavailability 
screening (e.g., BCS 
class)
– depicts apical and 
basal surface
– reflects villi like 
structures
– well defined cellular 
junctions
– easy to assess teeR 
for permeability 
measurements
– easily accessible 
– standardized
– reproducible 
– Papp useful for PBPK
– improved drug 
development by 
compound libraries
– predictions of 
compound properties
– prediction of intestinal 
permeability and 
improvement
– sample variability
– technical limitations
– poor correlation to 
in vivo rat absorption 
data (since, e.g., 
no available human 
absorption data for 
pesticides)
– technical limitations 
(sufficient water 
solubility needed, 
dependence on 
shipment)
– 7-10 days for  
polarization
– technical limitations
– only passive diffusion
– no metabolism
– poor correlation  
to in vivo rat  
absorption data
– technical limitations 
(sufficient water-
solubility, UV-activity 
needed)
– algorithms often  
based on 
simplifications (e.g., 
single barrier model, 
neglect of active  
and passive 
absorption)
– more complex 
compartmental  
models require high 
computing power
– definition of 
acceptance criteria 
(e.g., applicability 
domains, reference 
datasets, integrity 
tests,...?)
– higher 
standardization 
of the method 
including 
standardized 
integrity tests 
(SOP?)
– think about new 
approaches (new 
in vitro models? 
In silico models? 
Combination of 
both?) that cover all 
pathways
– simple system, 
applicable for 
screening purposes
– applicable for 
mixtures
– Standardized 
integration of in 
silico models  
into the preclinical 
process
– collection of all 
available compound 
information before 
testing
– no routine use 
in the regulatory 
context of 
chemicals and 
food, data from 
intestinal in vitro 
models can 
be treated as 
mechanistic  
add-on 
information
– clarify  
transporter 
activity and 
extent of  
activity in  
Caco-2 model
 Examples Advantages Limitations Issues and needs Memo
Models for intestinal absorption
Gordon et al.
Altex 32(4), 2015346
release surfactant apoproteins A, B, and D, proteases, antimicrobi-
al peptides, several cytokines and chemokines, and mucins, to the 
extracellular fluid lining the airspaces. Their functions include xe-
nobiotic metabolism, immune system regulation, and progenitor 
cell activity (Reynolds and Malkinson, 2010). Further branching 
of the respiratory tree gives rise to respiratory bronchioles, lined 
mainly by cuboidal ciliated epithelium and Club cells, followed 
by the alveolar ducts, which terminate in two or three alveolar 
sacs, the walls of which are comprised completely of alveoli. 
The alveolus is the structural unit of gas exchange. It is a 
spherical or polygonal air space approximately 250 µm in di-
ameter and its thin walls are surrounded by a rich network of 
pulmonary capillaries. The alveolar compartment is lined with 
membranous pneumocytes, known as type I alveolar epithelial 
cells (ATI), and granular pneumocytes, called type II alveolar 
epithelial cells (ATII) (Fehrenbach, 2001). ATI cells are large, 
thin squamous cells that cover 90-95% of the alveolar surface. 
These cells are involved in gas exchange and form an immu-
nological barrier able to sense microbial products and generate 
inflammatory responses (Féréol et al., 2008; Williams, 2003). 
ATII cells are cuboidal, constitute around 15% of total lung 
cells and cover approximately 7% of the total alveolar surface. 
ATII cells synthesize, secrete and recycle all components of the 
surfactant that regulates alveolar surface tension (Fehrenbach, 
2001). They are responsible for lung defense, immune regula-
tion, epithelial repair and ion transport. In addition to surfactant 
phospholipids, they secrete antimicrobial products such as com-
plement, lysozyme, and surfactant proteins (SP). Also present in 
the alveolus are the pulmonary macrophages, which play a key 
role in defense of this compartment. 
4.1.1  Pulmonary epithelium for  
drug development
According to the European Lung Foundation and European 
Respiratory Society White Book (http://www.erswhitebook.
org), the burden of lung disease in Europe remains as high today 
as it was at the turn of the millennium, and is furthermore likely 
to remain so for several decades. Each year in 28 EU countries, 
lung diseases cause two-thirds of every million deaths, and at 
least 6 million hospital admissions, accounting for over 43 mil-
lion in-patient bed days. Therefore, there is an urgent unmet 
need for new lung disease treatments. For ethical reasons, stud-
ies in humans are restricted to some baseline investigations and 
a limited range of in vivo challenges (e.g., allergen, ozone, exer-
cise, diesel exhaust) used in conjunction with morphological as-
sessment of tissue biopsies or cells obtained by bronchoalveolar 
lavage (BAL) (Krishna et al., 1998; Salvi et al., 1999; Teran et 
al., 1995). Although providing valuable insight into inflamma-
tory cell and mediator changes in the disease context, they only 
provide a “snapshot” and are not amenable to detailed mecha-
nistic studies. Consequently, there has been a high dependency 
on in vivo animal models to study mechanisms of human respi-
ratory diseases, where transgenic and knock out approaches per-
mit more functional assessment of a given molecule (Shapiro, 
2006), allowing for investigation of its relationship with the 
dynamics of the inflammatory process, or to study alterations 
in airway wall behavior. However, the utility of animal models 
universally employable but rather tailored to suit specific appli-
cations. Despite their varying complexity, non-animal models of 
the intestine described so far still remain overly simplified com-
pared to the in vivo situation, as they do not include feedback 
mechanisms or aspects of the gut microbiota, immune system, 
innervation or specific hormonal controls. Further efforts and 
technological innovations are therefore needed to further im-
prove and exploit intestinal models in order to meet the growing 
requirements of industry and researchers. Several new methods 
and technologies are currently being developed (Alépée et al., 
2014; Hartung, 2014) including (i) advanced human intestinal 
three-dimensional co-culture models with representation of in-
tact vascularization, (ii) integration of non-invasive biochip and 
sensor imaging technologies, (iii) implementation of computer-
controlled bioreactor and microfluidic systems and (iv) improved 
biomaterial and biomimetic approaches (e.g., 3D printing).
4  Non-animal models of the lung  
in research, industrial applications and  
regulatory toxicology
4.1  General introduction
The essential function of the lungs is gas exchange, involving 
transfer of oxygen from the air into the blood and carbon dioxide 
from the blood into the air. This is achieved via transport of air 
through the conducting airways of the upper and lower respirato-
ry tract to the respiratory portion of the lung where gas exchange 
takes place. The pulmonary epithelial surface is the first site of 
contact for inhaled environmental materials (noxious gases, an-
thropogenic and natural particulates, including pathogens) and so 
its barrier properties are centrally crucial for tissue homeostasis; 
equally, the epithelium represents a barrier for inhaled drug deliv-
ery, and transport across it is required for drug efficacy. As in the 
intestinal tract, the junctional complexes (tight junctions and ad-
herent junctions) between the epithelial cells play important roles 
in the homeostasis of the respiratory tract and the maintenance 
of mucosal immunity (Davies, 2014). However, it is important 
to recognize that the functions of the epithelium change along 
the respiratory tract, which is evident in the change in epithelial 
structure from proximal to distal regions of the lung. 
The epithelium of the trachea and large bronchi is typified 
by pseudostratified epithelium with basal cells supporting co-
lumnar ciliated epithelium and mucous secreting goblet cells 
(McDowell et al., 1978). Secretions from the goblet cells and 
submucosal mucous glands form a viscous fluid layer overlying 
the respiratory epithelium to protect the epithelial surface. The 
fluid contains water, mucins, ions, cytoprotective molecules 
such as antioxidants, and antimicrobial substances including 
immunoglobulin A (IgA) and lysozyme (Swindle et al., 2009). 
This viscous layer traps inhaled particles, microorganisms and 
sloughed off epithelium, which are then moved via ciliary ac-
tion of the respiratory epithelium towards the pharynx.
The bronchioles (< 1 mm diameter) have ciliated columnar 
respiratory epithelium with some Club cells (formerly known 
as Clara cells) and a few goblet cells. Club cells are non-ciliated 
cuboidal secretory cells. They are a source of secretoglobin and 
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4.2  Ex vivo lung models
Ex vivo lung cultures are convenient models for analyzing in-
teractions of environmental matter or pathogens in a three-di-
mensional tissue context of the airway or lung parenchyma, as 
well as for evaluation of drug responses and toxicity. Human 
precision-cut lung slices (PCLS), an ex vivo model consisting 
of all relevant cell types in their microanatomical environment 
(de Kanter et al., 2002), are well-established in pharmacologi-
cal testing (Sturton et al., 2008), analysis of allergic immune re-
sponses (Wohlsen et al., 2003) and studies of xenobiotic metabo-
lism (Lauenstein et al., 2014). There is also emerging literature 
concerning the use of ex vivo lung perfusion as a tool for experi-
mental research (Nelson et al., 2014). Originally developed to 
allow lungs to be assessed for their physiological and functional 
parameters prior to transplant, the technology is a powerful tool 
that enables isolated organ modification and evaluation, although 
it is currently applied only to small and large animal models due 
to limited access to human lungs. For disease-related studies, 
bronchial biopsies can be obtained from individuals with res-
piratory diseases or healthy control subjects by fiberoptic bron-
choscopy, and have been used ex vivo for short term experiments 
to analyze disease mechanisms. For example, explant models 
have been used to demonstrate the involvement of T cells in al-
lergic inflammation and to analyze signaling pathways involved 
in these responses (Hidi et al., 2000; Jaffar et al., 1999; Lordan 
et al., 2001; Vijayanand et al., 2010). While these models ben-
efit from retaining the normal lung tissue architecture, they are 
limited by their relatively short term viability, and the barrier 
properties of the epithelial layer are compromised by exposure 
of the whole excised tissue sample to challenge agents.
4.3  Reconstructed human lung models in vitro
4.3.1  Cell lines (standardization and validation)
Immortalized human lung epithelial cell lines (exemplifying 
bronchial, Club and alveolar epithelial phenotypes) have been 
established from cancers or by viral transformation of cells 
from normal lung tissue (Tab. 4). Cell line-based models are 
widely used both for pathophysiological studies of responses 
of the barrier to endogenous and exogenous agents and their as-
sociated signaling pathways, and for transport studies across the 
epithelial barrier. They are convenient, provide high throughput 
capacity, and are more economical than in vivo experiments. 
However, they also have some limitations in that they are fre-
quently used as a single cell type in monolayer culture, they 
may have an atypical phenotype (e.g., derived from adenocar-
cinomas) and their tight junctions may not be representative of 
the target tissue. Furthermore, their drug transporters may not 
be typical of normal lung epithelium, although these have been 
recently evaluated in five commercially available immortalized 
lung cell lines (Calu-3, BEAS2-B, NCI-H292, NCI-H441 and 
A549) by liquid chromatography-tandem mass spectrometry-
based approaches (Sakamoto et al., 2015), allowing comparison 
with data from primary lung cells (Sakamoto et al., 2013). Al-
though immortalized, ideally these cells should be used within 
a defined range of passages to ensure that their phenotypic char-
acteristics remain consistent. 
to understand human diseases such as asthma and chronic ob-
structive pulmonary disease (COPD) and for the development 
of therapeutics is a topic of considerable debate (Holmes et al., 
2011). Of major concern is the failure of animal models to repro-
duce the complex interplay between genetic and environmental 
stimuli that underlies many chronic human diseases. Recogni-
tion of the importance of these gene-environment interactions 
in disease pathogenesis has led to a major shift in focus to the 
function of the pulmonary epithelium, since it is the interface 
with the external environment. As will be detailed below, ac-
cess to human airway tissue has allowed development of ex vivo 
and in vitro models of the human airway epithelium that allow 
mechanistic studies that could not be performed ethically in vivo 
(Swindle and Davies, 2011). These studies range in their level 
of complexity from simple monocultures with little structural 
organization to complex three-dimensional cultures containing 
many cell types that are organized into a structure that retains 
(ex vivo tissue explants) or mimics (tissue engineered in vitro 
models) some in vivo elements (Blume and Davies, 2013). 
4.1.2  Pulmonary epithelium for drug delivery
The inhaled route offers an efficient mechanism for delivery 
of drugs either for treatment of local disease or as a route of 
administration for systemic therapies. For local delivery, cur-
rent technology offers efficient and reproducible pulmonary 
deposition of aerosol medicines allowing delivery of high local 
concentrations of active drug with a lower drug burden for the 
rest of the body (Ruge et al., 2013). For systemic delivery, the 
enormous surface area of the gas exchange region of the lung 
and relatively low enzymatic activity offers advantages for sys-
temic absorption and avoids liver first pass metabolism, reduc-
ing potential side effects and achieving a quick onset of action 
(Labiris and Dolovich, 2003; Patton and Byron, 2007). How-
ever, regardless of the progress that has been made in pulmo-
nary deposition of inhaled drugs, no significant advances have 
been made for pulmonary drug delivery beyond the treatment 
of some respiratory diseases (Ruge et al., 2013). One impor-
tant reason for this is the limited knowledge about the fate of 
inhaled drugs or carrier particles after deposition in the lungs 
(e.g., absorption across the alveolar epithelium and targeting of 
specific regions or cells within the lungs). Furthermore, prior 
to contact with the epithelial cells, drug particles delivered to 
the respiratory tract have to overcome the non-epithelial pul-
monary barrier of surfactant, alveolar macrophages, mucus and 
the mucociliary escalator. Mucus is a viscoelastic and adhesive 
gel that protects the surface of the airways by limiting contact 
of the epithelial cell surface with potentially damaging inhaled 
substances. Most foreign particulates, including conventional 
particle-based drug delivery systems, are efficiently trapped in 
human mucus layers. Trapped particles are then removed within 
seconds to a few hours depending on anatomical location. The 
penetration of mucus can be affected by particle size and surface 
chemistry (Schuster et al., 2013), and new mucus-penetrating 
particles that may avoid rapid mucus clearance mechanisms are 
under development for use in drug delivery (Lai et al., 2009). 
For these studies, access to systems that enable reliable assess-
ment of drug transport and metabolism are essential.
Gordon et al.
Altex 32(4), 2015348
Tab. 4: Cell-based models for pulmonary research
Cell Lines Calu-3 
16HBE 140-
H441
BEAS 2B
H292
1HAeo-
VA10
9Hteo-
HTE67tsa209o-
NCF3
IB3-1
CFt43
CFt1
JMe/CF15
CFBe41o-
CFte29o-
CFDEo-/6REP-
CFtR
CFt-1
CFt-3
– easily accessible
– polarization
– reproducible
– information on 
active transport
– reasonably 
accessible
– polarization
– information on 
active transport
– easily accessible
– polarized 
– reproducible
– information on 
active transport
– allows for 
mechanistic 
studies, response 
to cytokines, 
pathogens, etc.
– Well suited for 
mucus/mucin 
gene expression 
studies
– express tight 
junctions  
and mucin
– Defective DF 
transmembrane 
conductance 
regulator: allow  
for study of  
ion and fluid 
transport, 
pharmacological 
testing in  
diseased state
– single cell type
– no mucus layer
– adenocarcinoma cell 
line may have untypical 
phenotypes
– single cell type
– no mucus layer
– virally transformed cell 
line may have untypical 
phenotype
– single cell type
– features of bronchiolar 
and alveolar epithelium
– single cell type
– non-barrier forming: 
cannot be used for 
transport studies
– single cell type
– does not polarize: 
cannot be used for 
transport studies
– single cell type
– single cell type
– single cell type
– don’t form tight barrier
– single cell type
– does not form a tight 
barrier
– single cell type
– should be standardized 
with respect to 
acceptable levels of 
teeR and Papp limits 
for specific reference 
compounds
– variability dependent  
on culture conditions 
 
 
 
– express a number of 
key drug transporters 
and P- glycoprotein 
function comparable to 
human primary AtI-like 
pneumocytes
– no routine use 
in the regulatory 
context of 
chemicals and 
food, data  
from in vitro 
models can  
be treated  
as mechanistic 
add-on 
information
 Examples Advantages Limitations Issues and needs Memo
Central Airway Models
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ized (with respect to acceptable levels of TEER as well as Papp 
limits for specific reference compounds) to ensure reproducible 
results. The 16HBE 14o- cell line exhibits heterogeneous be-
havior which is highly dependent on culture conditions, lead-
ing to variable transport and permeability properties. However, 
by standardization of the culture conditions 16HBE 14o- cells 
can provide a discriminatory barrier to solute transport (Forbes 
et al., 2003). While 16HBE 14o- cells have been reported to 
exhibit morphological features including apical microvilli and 
cilia (Cozens et al., 1994), in our experience cilia are absent 
from polarized 16HBE 14o- cultures.
In addition to their use for toxicology (Forti et al., 2010, 
2011) and drug transport studies, 16HBE 14o- and Calu-3 cell 
lines are frequently used for analysis of pathways involved in 
barrier function in response to environmental agents including 
allergens (Vinhas et al., 2011; Wan et al., 2001), particulates 
(Banga et al., 2012), cigarette smoke (Heijink et al., 2012) or 
viral infections (Harcourt et al., 2011; Rezaee et al., 2011). The 
other frequently used bronchial epithelial cell line, BEAS2B 
(Reddel et al., 1988), is not of value for transport studies as 
it fails to form an appreciable barrier (Forbes and Ehrhardt, 
2005). However, this cell line is routinely used for mecha-
nistic studies, responding to cytokines, danger signals and 
pathogens (Edwards et al., 2006; Hara et al., 2012). The NCI-
H292 mucoepidermoid bronchial epithelial cell line (Carney 
et al., 1985) also fails to polarize, but is the cell line of choice 
for studies of mucus and mucin gene expression (Koff et al., 
2008; Shao and Nadel, 2005). This cell line also can be used 
as a substitute for monkey kidney cells for isolation of a broad 
A variety of human bronchial epithelial cell lines have been 
tested with respect to their transepithelial transport kinetics and 
their potential use in predicting in vivo lung absorption. These 
include cell lines such as the adenocarcinoma cell line Calu-3 
(Shen et al., 1994) and the SV-40 transformed cell line 16HBE 
14o- (Cozens et al., 1994), both of which are able to form tight 
junctions and polarize when grown on semi-permeable fil-
ter supports (e.g., Transwell® inserts). The barrier properties 
of these cell lines have been described (Ehrhardt et al., 2002; 
Forbes et al., 2003; Mathias et al., 2002) and detailed protocols 
for their culture, maintenance, growth and permeability assess-
ment have been published (Meaney et al., 2002), but it should 
be noted that culture methods vary between laboratories, e.g., 
passage number, seeding density, submerged or air-liquid inter-
face, use of extracellular matrices, media composition, duration 
of culture – see Forbes and Ehrhardt (2005). 
The Calu-3 cell line is available from the American Type Cul-
ture Collection and is most frequently used for transport studies. 
Permeability data for small lipophilic molecules across Calu-3 
monolayers also suggests that the cell line is a suitable model to 
examine the transport of low molecular weight substances and 
xenobiotics (Foster et al., 2000; Zhu et al., 2010). TEER val-
ues for Calu-3 monolayers grown on filter supports range from 
around 300 to 2500 Ω cm2 (Foster et al., 2000; Loman et al., 
1997). While there is an inverse relationship between TEER and 
Lucifer yellow flux, once the monolayers achieve an appreci-
able TEER (> 300 Ω cm2), there is very little change in Lucifer 
yellow flux across monolayers with higher TEER values (Foster 
et al., 2000). Therefore, use of this cell line should be standard-
Tab. 4: Cell-based models for pulmonary research
Primary Cells
Cell Lines
Primary Cells
Primary cultures, 
AlI models 
(e.g., MucilAir, 
epiAirway)
A549
AtI cells (via 
differentiation of 
AtII cells)
– available 
commercially 
– mucociliary 
differentiation, 
– polarization
– information on 
active transport
– metabolic 
properties 
consistent with 
AtII cells in vivo
– polarized with 
good teeR
– information on 
active transport
– inter-subject variability
– do not form tight 
junctions 
– leakiness limits utility in 
examining the transport 
of low molecular drugs 
and xenobiotics
– not readily  
accessible – requires 
access to fresh lung 
tissue for preparation 
of AtII cells
– inter-subject variability
– should be standardized 
with respect to 
acceptable levels of 
teeR and Papp  
limits for specific 
reference compounds
– differentiated function 
may be lost over time 
if not appropriately 
cultured
– limited studies to 
evaluate this system
– clarify fields 
of (regulatory) 
acceptance
 Examples Advantages Limitations Issues and needs Memo
Central Airway Models
Peripheral Airway Models
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Many studies have employed primary human cells as monol-
ayer cultures to evaluate responses of the cells to environmen-
tal agents. Most frequently, the cultures are plated directly onto 
collagen-coated culture plastic dishes and are not polarized. 
However, such approaches have allowed evaluation of cells de-
rived from the airways of normal or diseased (asthma, COPD, 
CF) volunteers offering the potential to compare responses and 
identify dysregulated pathways that may contribute to disease. 
Several studies with PBECs from non-asthmatic and asthmatic 
individuals have highlighted differences in the cellular response 
after exposure to environmental agents with the potential to 
cause epithelial damage. For example, it has been shown that 
monolayer cultures of PBECs derived from moderate-to-severe 
asthmatic individuals have a deficient innate immune response 
to rhinovirus infection by producing less interferon (IFN)-β 
(Wark et al., 2005), and this is paralleled by higher levels of 
the Th2-promoting chemokine, thymic stromal lymphopoietin 
(TSLP) (Uller et al., 2010). Based on the observation that ex-
ogenous IFN-β restores the anti-viral response and suppresses 
viral replication (Cakebread et al., 2011), clinical trials using 
inhaled IFN-β as a new treatment for virus-induced exacerba-
tions have reported a beneficial effect in a subgroup of patients 
with severe asthma (Djukanović et al., 2014). Modulation of 
the basal cell phenotype by cigarette smoke and growth factors 
such as EGF has also been extensively studied (Shaykhiev et 
al., 2013a,b).
Methods for the isolation and maintenance of ATII cells 
from human lung tissue are well established (Robinson et al., 
1984; Witherden and Tetley, 2001). They all involve proteolytic 
(elastase, dispase and/or trypsin) digestion and many utilize 
density gradient separation and negative selection. This ap-
proach can provide at least 1×106 cells/g of lung tissue, yield-
ing 95% pure ATII cells (Bingle et al., 1990; Witherden et al., 
2004). Modifications of this method using different enzymes 
and positive selection by flow cytometry (Marmai et al., 2011), 
antibody-coated magnetic beads (Ehrhardt et al., 2004) or dif-
ferential adherence (Witherden and Tetley, 2001) have been re-
ported to yield higher ATII cell purity (up to 98%). The cells 
should be characterized with at least two epithelial markers, 
including Sp-C and E-cadherin, to determine purity (Jenkins et 
al., 2012). Cultured fetal lung epithelial cells differentiate into 
ATII cells following treatment with dexamethasone plus cAMP 
and isobutylmethylxanthine (DCI); similarly culturing adult 
ATII cells for 5 days on collagen-coated dishes with DCI for the 
final 3 days promotes lamellar body production and induction 
of a subset of hormone responsive genes in cultured adult cells, 
similar to those in the fetal cells (Ballard et al., 2010). In culture, 
ATII cells secrete the phospholipids characteristic of pulmonary 
surface active material and engage in immune signaling (Payne 
et al., 2004; Thorley et al., 2005, 2007). Primary alveolar epi-
thelial cells have also been used to assess the pathogenesis of 
influenza infection, including H5N1 (Chan et al., 2009) and the 
interaction of alveolar epithelial cells with nanoparticles which 
can reach the periphery of the lung (Kemp et al., 2008). The 
major challenges of using primary ATII cells relate to viability 
and fragility (they rarely survive freezing), limited replicative 
capacity when cultured, and purity (mesenchymal cell “contam-
spectrum of respiratory viruses, but not all strains of influenza 
viruses (Hierholzer et al., 1993), and for studies of rhinovirus 
infection (Heinecke et al., 2008).
A number of cancer cells have been identified which have 
features of peripheral lung cells (Gazdar et al., 1990). The most 
commonly used cell lines are A549 (Lieber et al., 1976) and 
H441 (Brower et al., 1986). A549 cells are commonly used as a 
model of ATII cells, as they were originally reported to contain 
lamellar bodies (Balis et al., 1984; Lieber et al., 1976). Over 
the passage of time this differentiated function may be lost, es-
pecially if specific culture conditions are not employed (Speirs 
et al., 1991). A549 cells do not appear to form functional tight 
junctions (Winton et al., 1998) but they exhibit some metabol-
ic and transport properties consistent with ATII cells in vivo. 
However, the leakiness of the A549 cell line limits its utility 
in examining the transport of low molecular weight drugs and 
xenobiotics (Foster et al., 1998). H441 cells have also been 
evaluated as models of the peripheral lung. These cells, which 
were derived from a papillary adenocarcinoma of the lung, have 
features characteristic of Club cells (Gazdar et al., 1990) and 
have been used as a model of bronchiolar epithelium (Bruce 
et al., 2009). However, more recently, it has been found that 
culture of H441 cells on semi-permeable filter supports results 
in formation of electrically tight monolayers (peak TEER values 
of approximately 1000 Ω cm2 after 8-12 days in culture) which 
are able to differentiate paracellularly transported substrates ac-
cording to their molecular weight (Salomon et al., 2014). In this 
model, the cells express a number of key drug transporters and 
P-glycoprotein function was found to be comparable to human 
primary ATI-like pneumocytes.
Immortalized cell lines derived from states of human disease 
are mainly from cystic fibrosis (CF) patients (Tab. 4) and several 
cell lines with defective CF transmembrane conductance regula-
tor are available (Gruenert et al., 2004). These have utility for 
studies of ion and fluid transport and pharmacological testing. 
4.3.2  Primary lung cells
Several protocols have been established for in vitro culture of 
primary human airway epithelial cells (PBECs) obtained from 
bronchial brushings or biopsies (Bucchieri et al., 2002; Devalia 
et al., 1999). These samples can be routinely obtained using 
fiberoptic bronchoscopy performed on volunteers after ethical 
approval and informed consent; however the requirement for 
bronchoscopy limits availability of this approach to those with 
access to appropriate clinical facilities. For cell collection by 
bronchial brushing, care must be taken not to be too vigorous, 
as this causes bleeding and will reduce cell viability. Alterna-
tives to bronchoscopy include purchase of cells from commer-
cial suppliers (e.g., Lonza, Epithelix, MatTek) or use of resected 
or transplant tissue. The cells are generally grown in monolayer 
culture on collagen I coated dishes using defined growth me-
dium (e.g., BEGM from Clonetics) and can be expanded by 2-3 
passages; early passage cells (P0) can be reliably cryopreserved 
without loss of viability for subsequent use. These cells express 
basal cell markers including cytokeratin 5 and the transcription 
factor p63 (Hackett et al., 2011a) and have been used as models 
of basal cells. 
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al., 2010), mucociliary transport (Seagrave et al., 2012), airway 
toxicology (Mathis et al., 2013; Watson et al., 2010), electro-
physiology (Hirsh et al., 2008), and bacterial and viral infection 
studies (Deng et al., 2014; Mitchell et al., 2011; Palmer et al., 
2012; Ren and Daines, 2011; Ren et al., 2012). The MucilAir 
cultures have been characterized electrophysiologically and are 
fully functional: the activity of the main epithelial ionic channels, 
such as CFTR, EnaC, Na/K ATPase, etc. is preserved. Moreover, 
the epithelia respond in a regulated and vectorial manner to the 
pro-inflammatory stimulus TNF-α (Hardyman et al., 2013). A 
large panel of cytokines, chemokines and metalloproteinases 
has been detected (e.g., IL-8, IL-6, GM-CSF, MMP-9, GRO-α, 
etc.). Muco-ciliary clearance function is also present in Muci-
lAir, with mucus velocity values comparable to the in vivo situ-
ation (around 2 mm/min – Huang et al., 2011). Furthermore, 
with clear PET Transwell® inserts, the model is very practical 
and convenient to use, and suitable for most applications such 
as imaging, immunocytochemistry, toxicity tests, electrophysi-
ological studies (Ussing chamber measurements), assessment of 
drug permeation, drug formulations, etc.
The airway epithelium is a prime entry portal of xenobiotics 
into the body upon inhalation. Knowledge of toxicokinetics is 
needed to estimate the possible range of target doses at the cell 
or tissue level that can be expected from realistic external human 
exposure scenarios to inhaled compounds. This information is 
crucial for determining the dose range that should be used for in 
vitro testing. Kinetics in the in vitro system and dose-response 
information is also crucial to translate in vitro results to the hu-
man in vivo situation (Adler et al., 2011). Reconstructed human 
airway epithelium assays represent a promising in vitro tool 
to evaluate respiratory absorption, giving input parameters for 
PBTK modelling. By transposing the Caco-2 protocol (Hubat-
sch et al., 2007) to three-dimensional airway epithelial models, 
trans-epithelial permeability of drug candidates or xenobiotics 
can be used to assess the upper-airway permeability of poten-
tial drugs, formulations or xenobiotics. Measuring the rate of 
compound across EpiAirway (Agu et al., 2006; Leonard et al., 
2005, 2007) and MucilAir (Reus et al., 2014) provides insight 
into the ability of different compounds to cross the respiratory 
epithelia. In permeability studies different compounds are uti-
lized at known concentrations and in two directions (apical to 
basolateral and basolateral to apical). To evaluate the rate of 
absorption, the permeability coefficient (Papp) is calculated for 
each compound. To assess whether a compound undergoes ac-
tive efflux, apical (A) to basolateral (B) transport is measured 
(A→B) and vice versa (B→A). The ratio of B→A/A→B measure-
ments (asymmetry index) is then determined. If the value of the 
asymmetry index is greater than 1.5, the compound is subject to 
active efflux. Known Papp values range over two orders of mag-
nitude: 4.94 x 10-5 (ibuprofen) to 2.06 x 10-7 cm/sec (nadolol) 
with a 240-fold difference between the highest and the lowest 
Papp value (Fig. 2).
In addition to consideration of culture models, methods for 
delivery of drugs, particles or gases to the pulmonary surface 
also require reliable, easy-to-handle and efficient technolo-
gies for direct aerosol-to-cell delivery. The well-characterized 
commercially available VITROCELL® exposure chamber sys-
ination” in disease states) (Jenkins et al., 2012). ATII cells are 
the progenitors of ATI cells and acquire features of this cell type 
when cultured (Demling et al., 2006; Swain et al., 2008). Meth-
ods have been developed to promote this trans-differentiation: 
this involves purification of ATII cells by a combination of cell 
attachment, density gradient centrifugation and positive mag-
netic cell sorting followed by seeding the cells onto permeable 
supports. Under appropriate culture conditions, the ATII cells 
differentiate into an ATI-like phenotype within approximately 
one week, achieving TEER values of ~2,000-2,500 Ω cm2 suit-
able for transport studies (Daum et al., 2012; Elbert et al., 1999) 
and showing an increase in caveolin-1 positive, Sp-C negative 
cells (Fuchs et al., 2003). ATII cells have also been obtained 
from fibrotic lung, however they are often contaminated, with 
only approximately 80% exhibiting classic ATII cell character-
istics (Maher et al., 2010). 
4.3.3  Fully differentiated 3D human  
airway epithelial models 
As an extension of the PBEC monolayer model, use of in vit-
ro differentiated PBECs offers an epithelial model that more 
closely recapitulates the airways in vivo. Different techniques 
have been developed to make three-dimensional cultures, by 
providing a microenvironment or architecture closer to the in 
vivo situation. Among these techniques are cellular matrix scaf-
folds, hanging drop cultures, perfusion culture chambers and 
air-liquid interface (ALI) cultures. However, in order to simu-
late in vivo lung conditions, ALI cultures seem to be most ap-
propriate – the basolateral side of the epithelium is immersed 
in the culture medium and the apical side is exposed to a hu-
midified air / 5% CO2 environment. Placing PBECs at an ALI in 
the presence of retinoic acid causes the epithelial cells to form 
a pseudostratified structure with basal cells supporting ciliated 
cells and mucus-producing goblet cells (Pezzulo et al., 2010), 
as occurs in vivo. Transcriptomic studies have shown that ALI 
cultures provide a good representation of the in vivo airway epi-
thelial transcriptome (Dvorak et al., 2011; Pierrou et al., 2007). 
Many in-house airway epithelial models based on primary hu-
man cells have been developed and used (Bérubé et al., 2010; 
Gray et al., 1996; Xiao et al., 2011). Two ALI systems named 
MucilAir (Epithelix) and EpiAirway (MatTek) are also com-
mercially available and ready-to-use. MucilAir distinguishes 
itself by having a uniquely long shelf-life: it can be maintained 
in a homeostatic state for a year. Furthermore, cultures from 
distinct anatomical locations are also available (nasal, tracheal 
or bronchial) and cell cultures can be obtained from diseased 
donors (asthmatic, allergic, COPD or CF) in the case of both 
MucilAir and EpiAirway systems.
In-house, MucilAir and EpiAirway cultures start with de-
differentiated cells, which then undergo a progressive differen-
tiation with time. After 14-21 days (EpiAirway) or 20-45 days 
(MucilAir) of culture the epithelia are fully ciliated and electri-
cally tight (TEER≈450 Ω cm2). EpiAirway cultures are available 
in a number of useful insert formats, and have been successfully 
utilized for numerous applications including airway drug deliv-
ery (Agu et al., 2006; Leonard et al., 2005, 2007), airway dis-
ease modelling (Bai et al., 2015; Freishtat et al., 2011; Watson et 
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ALI cultures have provided insights into pathogenetic mecha-
nisms, for example the ability of Th2 cytokines, IL-4 and IL-13, 
to skew bronchial epithelial cell differentiation towards goblet 
cell hyperplasia, increased mucin gene expression and mucous 
hypersecretion (Kanoh et al., 2011; Thavagnanam et al., 2011; 
Zuyderduyn et al., 2011). Furthermore, use of ALI cultures has 
allowed for comparisons of barrier properties, mucus produc-
tion and other responses of epithelial cells from asthmatic and 
healthy subjects, as well as the demonstration that tight junctions 
are reduced and mucus production and inflammatory cytokine 
induction are increased in cultures from asthmatic subjects (as 
observed in vivo). Such changes have been seen to correspond 
to an increase in ionic and macromolecular permeability (Xiao 
et al., 2011; Bai et al., 2015; Freishtat et al., 2011; Watson et 
al., 2010). It has also been shown that the permeability of the 
bronchial epithelial cell layer is only increased in asthmatic 
subjects after exposure to ozone or nitrogen dioxide (Bayram 
et al., 2002), and that mediator release is altered after exposure 
of ALI cultures from asthmatic donors to respiratory syncytial 
virus (RSV) or particulate matter (Hackett et al., 2011b). Us-
ing cells derived from patients with COPD, ALI cultures show 
higher baseline levels of cytokine expression and increased sus-
ceptibility to RSV infection, despite an increased IFN response 
tem is specially designed for direct contact between cells and 
components of the test atmosphere at the air/liquid interface. 
Recent studies suggest that application of an electrostatic field 
(referred to as ALI deposition apparatus, ALIDA) facilitates 
particle deposition efficiencies that are higher by factor > 20 
than the unmodified system (Panas et al., 2014). Another ap-
proach, the ALICE-CLOUD technology, utilizes principles of 
cloud motion for fast and quantitative delivery of aerosolized 
liquid drugs to pulmonary cells cultured under ALI conditions 
(Lenz et al., 2009, 2014). Aerosol-to-cell delivery was shown 
to be highly efficient, reproducible and rapid using aerosolized 
fluorescein as a surrogate drug. This type of approach may pave 
the way for screening of inhalable drugs under more physiolog-
ically relevant and hence potentially more predictive conditions 
than the currently used submerged cell culture systems (Lenz 
et al., 2013). Primary human alveolar epithelial cell (hAEpC) 
models can also be used for toxicity and transport studies for 
newly developed compounds and delivery systems (Daum et 
al., 2012). The so-called Pharmaceutical Aerosol Deposition 
Device On Cell Cultures (PADDOCC) system (Hein et al., 
2011) enables pharmaceutical formulations to be aerosolized 
and deposited as a dry powder aerosol onto ALI-grown alveolar 
epithelial cells.
Fig. 2: Comparative apparent permeability coefficient (Papp) of 30 compounds obtained on MucilAir airway epithelium
the absorption of test items was assessed after apical exposure, and the Papp of the chemicals across airway  
epithelium was measured. A panel of 30 compounds was tested to evaluate the ability of the assay to rank relative permeability  
(Papp A→B from 2.06 x 10-7 to 4.94 x 10-5 cm/s). 
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4.3.5  Stem cell-derived lung cells
While primary cell culture models are more able to recapitulate 
differentiated functions of the pulmonary epithelium, they are 
usually limited by the relatively small amount of material that 
it obtained at bronchoscopy or from resections. More recently, 
traditional stem cell differentiation protocols have been applied 
to human embryonic stem cells (hESCs) or induced pluripo-
tent stem cells (iPSCs) to evaluate their use for lung specific 
differentiation. Thus, transfection and culture procedures have 
been developed which facilitate the differentiation of hESCs 
into a pure (> 99%) population of ATII cells with morphological 
characteristics including lamellar body formation, expression 
of surfactant proteins A, B, and C, alpha-1-antitrypsin, and the 
CF transmembrane conductance receptor, as well as the syn-
thesis and secretion of complement proteins C3 and C5 (Wang 
et al., 2007). Protocols have also been developed whereby hu-
man embryonic stem cells can be differentiated into the major 
cell types of lung epithelial tissue (Van Haute et al., 2009). ATII 
cells have also been derived from iPSCs and have phenotypic 
properties similar to mature human alveolar type II cells (iPS-
ATII) (Ghaedi et al., 2014). Of note, use of a rotating bioreac-
tor culture system that provides an ALI is a potent inducer of 
ATI epithelial cell differentiation for both iPS-ATII cells and 
human ATII cells. iPS-ATII progenitor cells retain the ability 
to adhere to and proliferate within three-dimensional lung tis-
sue scaffolds and display markers of differentiated pulmonary 
epithelium (Ghaedi et al., 2013). This approach may provide 
a method for large-scale production of alveolar epithelium for 
tissue engineering and drug discovery. However, much research 
is needed to establish optimal conditions for growth of specific 
cell types and, as with the immortalized cell lines, to character-
ize their phenotypic properties. 
4.3.6  Co-culture and pathophysiological models
A significant limitation of many in vitro cell culture models is 
that they investigate responses only from one isolated cell type 
whereas in vivo, the interplay between many different cell types 
is crucial for cellular homeostasis. In order to address these com-
plex interactions in experimental models, considerable effort 
is currently being invested into the development of co-culture 
models and three-dimensional tissue constructs integrating cells 
and extracellular matrix components to more closely mimic the 
in vivo state. A variety of co-culture models have been described 
using many different combinations of cell types. The simplest 
co-culture models use differentiated or undifferentiated airway 
epithelial cells in the apical compartment of semi-permeable 
filter support units and other cell types in the basal compart-
ment. Adherent cells such as fibroblasts or endothelial cells 
can also be cultured in close contact with the epithelial cells on 
the under-surface of the filter insert (Pohl et al., 2010). A com-
mercially available co-culture model that allows direct contact 
between the differentiated airway epithelium and a fibroblast-
containing subepithelial matrix is also available (EpiAirwayFT, 
MatTek). These co-culture models represent a valuable tool to 
analyze epithelial-mesenchymal signaling, which is believed to 
play an important role in airway inflammation and remodeling 
in asthma. For example, fibroblast activation has been observed 
(Schneider et al., 2010). ALI cultures are also useful to analyze 
ciliary beat frequency in response to various stimuli (Bayram et 
al., 1998; Devalia et al., 1992).
While the focus of this section of the current review is on the 
surface epithelium, it is also worth noting that primary human 
bronchial epithelial cells can differentiate into three-dimen-
sional spheroids with a lumen and cells that secrete MUC5B 
mucin (a marker for glandular mucous cells) together with 
lysozyme, lactoferrin and zinc-a2-glycoprotein (markers for 
glandular serous cells) when grown on Matrigel™ (Wu et al., 
2011). This in vitro model system of respiratory tract glandular 
acini is relevant for investigations into mechanisms that lead 
to the submucosal glandular hyperplasia seen in COPD, CF 
and chronic rhinosinusitis. Spheroids can also be derived from 
bronchial brushing and are free floating with ciliated cells on 
the outer surface of the spheroid (Deslee et al., 2007). These 
models have been used for studying processes involved in 
morphogenesis and branching (Hayden, 2012; Hubatsch et al., 
2007) and may also offer pharmaceutical companies potential 
for high throughput screening using approaches similar to those 
employed for evaluating anti-cancer drugs (Kunz-Schughart et 
al., 2004). ATII cells have also been cultured as spheroids and 
expressed mature morphological characteristics including la-
mellar bodies. SP-C mRNA, a specific protein for ATII cells 
was reported to be expressed only in cells forming spheroids 
(Takahashi et al., 2004).
4.3.4  Immortalization of primary cells  
without loss of differentiation capacity
While monolayer and ALI models contribute significantly to 
our understanding of disease mechanisms, they are limited due 
to the relatively low number of cells that can be collected and 
grown from each subject and there is the potential for cells to 
lose their characteristics after long term culture (Yoon et al., 
2000). However, recent advances involving induced expression 
of human telomerase reverse transcriptase (hTERT) to prevent 
replicative senescence and expression of the cell cycle protein 
cdk4 (Ramirez et al., 2004) has enabled immortalization of 
epithelial cells in culture without loss of their ability to differ-
entiate when taken to an ALI (Vaughan et al., 2006). More re-
cently, a human airway epithelium-derived basal cell line with 
multipotent differentiation capacity has been established by im-
mortalization using a retrovirus expressing hTERT (Walters et 
al., 2013). Such an approach might be useful to generate cell 
lines from asthma-derived cells, although any such lines would 
need careful phenotypic characterization. 
An immortalized ATII cell line has been generated by trans-
duction with the catalytic subunit of telomerase and simian 
virus 40 large-tumor antigen (Kemp et al., 2008). Immuno-
chemical and morphologic characterization demonstrated an 
ATI-like cell phenotype with expression of caveolin-1 and 
receptor for advanced glycation end products (RAGE). This 
cell line has been used to study innate immune responses to 
bacterial ligands and the role of TLR signaling (Thorley et 
al., 2011), however, the TT1 cell line did not form tight junc-
tions and was not suitable for drug transport studies (van den 
Bogaard et al., 2009).
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4.4  Chip technology
Currently, substantial effort is being invested into the develop-
ment of new devices and multicellular 3D co-culture models 
(Andersen et al., 2014) to study airway epithelial barrier func-
tions in vitro using tissue engineering approaches. Since airway 
epithelial cells are cultured at an ALI, alternative methods have 
been developed to monitor barrier functions instead of using 
chop-stick electrodes that require the cultures to be submerged, 
allowing electrical contact to be made across the epithelial layer. 
By using electrical impedance, the electrical barrier properties 
of epithelial cells can be monitored continuously without sub-
merging the cultures (Sun et al., 2010). A more advanced model 
of the pulmonary epithelium is the so called “lung-on-a-chip” 
model, a device with alveolar epithelial cells on the apical and 
endothelial cells on the basolateral side of a porous membrane 
(Huh et al., 2010; Stucki et al., 2015). In this model, the cells are 
supplied with nutrition via microfluidic flow of medium which 
also allows introduction of immune cells into the model. Ad-
ditionally, the device is built of flexible materials, which allow 
controlled stretching of the cells on the membrane to simulate 
the cyclical stretch of the lung tissue during inhalation and ex-
halation. Other models have used tissue engineered matrices to 
support airway cells in a three-dimensional tissue equivalent 
(Choe et al., 2006). Using biocompatible hydrogels as an ECM 
analogue offers the advantage of modulating the ECM stiffness, 
which is of interest in asthma remodeling processes. For ex-
ample, it has been shown that increased ECM stiffness induces 
fibroblast differentiation and results in increased expression of 
α-smooth muscle actin (Huang et al., 2012).
4.5  In silico modeling
Computer modeling has also long been used to study kinetics 
of absorption in the lung. Underpinning this work is the com-
puter modeling of gaseous exchange in the lung and in the body 
(Conway, 1986; Joyce et al., 1993), and an understanding of the 
detoxification of toxins by the lung (Evelo et al., 1993). Com-
puter modeling and multimodality medical imaging have also 
been used to study the three-dimensional spatial distribution of 
a metered dose inhaler and two nebulizers within the lung of 
humans (Fleming et al., 1996). In more recent times, an empha-
sis on population pharmacokinetic modeling has been seen with 
respect to the assessment of the absorption of pulmonary-direct-
ed active compounds (Bartels et al., 2013); three-dimensional 
imaging of particle distribution in and clearance from the lung 
also constitutes an area of recent interest (Burgreen et al., 2010; 
Longest et al., 2012; Sturm, 2013). This work is complemented 
by somewhat simpler compartmental models (Weber and Hoch-
haus, 2013). There are also a limited number of in silico quanti-
tative structure-activity relationships to predict lung retention of 
solutes after inhalation (Cooper et al., 2010), or chemical sensi-
tization of the lung (Mekenyan et al., 2014). 
While the presented material both within this chapter in gen-
eral as well as in the current section has focused on epithelial 
barrier function in the lung, there is a need to understand how 
this cellular function fits into the integrated function of the pul-
monary system. To date, relatively little attention has been paid 
to modeling at the cellular or subcellular level in the lung, or to 
in response to epithelial challenges including physical damage 
(Malavia et al., 2009; Thompson et al., 2006), viral infection 
(Tomei et al., 2008) or mechanical strain to simulate the effect 
of bronchoconstriction on the epithelium (Choe et al., 2003). 
Similarly, by co-culturing airway epithelial and endothelial 
cells, it has been shown that cell-cell communication involving 
soluble endothelial-derived factor(s) causes a significant reduc-
tion in paracellular permeability compared to that seen when 
epithelial or endothelial monolayers are studied in monoculture 
(Chowdhury et al., 2010).
The complexity of these models can be increased further by 
combining more than two different cell types, however one 
critical step in these approaches is optimization of media com-
patibility, as different cell types have differing requirements for 
supplements and co-factors and their behavior can be markedly 
modified by changing culture conditions. Using membrane filter 
supports, a triple cell culture model of the bronchial epithelium 
has been developed with airway epithelial cells cultured on the 
upper surface of the filter support until confluent, followed by 
introduction of macrophages onto the apical surface and den-
dritic cells basolaterally (Lehmann et al., 2011; Rothen-Rut-
ishauser et al., 2005). In this model, macrophages and dendritic 
cells were able to make contact with each other without break-
ing down the epithelial barrier by expression of tight junction 
proteins; an exchange of particulates between macrophages and 
dendritic cells was also possible (Blank et al., 2011). Another 
triple cell culture model is described by Farcal et al. (2013). The 
authors established an in vitro alveolar barrier by co-culturing 
three human cell types (epithelial, endothelial and monocytes), 
and studied the mechanisms of toxicity induced by amorphous 
silicon dioxide nanoparticles. The induction of a pro-inflamma-
tory state was shown, as evidenced by a high release of TNF-α 
and IL-8. To specifically study the interaction between epithe-
lium and subepithelial cells, a co-culture model has been devel-
oped using bronchial fibroblasts embedded in extracellular ma-
trix overlaid first with dendritic cells, and then with bronchial 
epithelial cells at the air-liquid interface; this model has been 
used to show that the structural cells regulate the capacity of 
dendritic cells to produce the chemokines CCL17, CCL18, and 
CCL22 (Hoang et al., 2012).
A primary co-culture system to simulate the human alveolar-
capillary barrier has been developed using human pulmonary 
microvascular endothelial cells and primary human ATII cells 
on opposite sides of a permeable filter support. Within 7-11 days 
of co-culture, the ATII cells partly transdifferentiated to ATI-like 
cells, and tight junctions and adherent junctions were evident. 
The model demonstrated polarized cytokine release and may be 
useful for studying mechanisms of lung injury in both the epithe-
lial (intra-alveolar) and the endothelial (intravascular) compart-
ments (Hermanns et al., 2009). A triple cell co-culture model 
composed of primary ATI-like cells isolated from human lung 
biopsies, macrophages and dendritic cells has also been devel-
oped (Lehmann et al., 2011). In this model, epithelial integrity 
was high (1113 ±30 Ω cm2), demonstrating the potential of the 
model to offer a novel and more realistic cell co-culture system 
to study possible cell interactions of inhaled xenobiotics and their 
toxic potential on the human alveolar type I epithelial wall.
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priority setting (Marquart et al., 2012). It can also serve for risk 
assessment, such as route-to-route extrapolation, interspecies 
extrapolation, and internal exposure-based waiving, as outlined 
in the EURL ECVAM strategy for achieving 3Rs impact in the 
assessment of toxicokinetics and systemic toxicity (Bessems et 
al., 2015).
5.1  Skin
5.1.1  Acceptance
Of all non-animal barrier models, the ex vivo test for dermal 
absorption using human skin has probably found the widest 
regulatory acceptance. Today, this method is considered by 
many authorities as stage 2 in a tiered testing strategy, triggered 
if the worst case default assumptions (stage 1) do not lead to a 
satisfactory assessment (Niemann et al., 2013). We could sub-
stantiate this observation by analyzing the type of information 
on dermal absorption that applicants submitted to the German 
Federal Institute for Risk Assessment (BfR) in order to satisfy 
data requirements of pesticide and biocide regulations (source: 
eASB, internal study data base; date accessed: 12/03/2014). Of 
all studies with a report date in 1993, i.e., for which the study 
report was finalized in 1993 and which were – accordingly – 
performed in the month before, 47% used an ex vivo method 
and 41% were performed in vivo in animals. A similar picture 
was obtained for the report date in 2003 with, again, 47% ex 
vivo and 46% in vivo in animals. This ratio changed dramati-
cally in the years following the publication of the OECD test 
guideline 428 in 2004 (OECD, 2004a) and the accompanying 
guidance document (OECD, 2004b). For report dates in 2010, 
2011, 2012 and 2013, remarkable percentages of 84, 71, 67 and 
85% of ex vivo studies, respectively, were counted, compared to 
7-15% of in vivo studies. Interestingly, there also seemed to be 
a tendency towards submission of more non-testing data (21% 
in 2011/2012).
Similarly, alternative tests are well established when testing 
for skin/eye irritation and corrosion under REACH. Meanwhile 
the combination of OECD TG 439 (in vitro skin irritation) and 
OECD TG 431 (in vitro skin corrosion) allow the classification 
of corrosive and irritant substances, as well as the identifica-
tion of substances that do not require classification and labeling. 
With regards to activated carcinogens, the use of metabolically 
competent skin models in conjunction with the Comet assays is 
currently pre-validated for regulatory suitability in an ongoing 
collaboration between Cosmetics Europe and the partners of a 
project funded by the German Federal Ministry of Education.
5.1.2  Needs 
In reality, exposure to a certain drug or chemical via the skin 
occurs over a wide range of conditions that differ with regard 
to factors known to influence the extent to which the substance 
becomes systemically available. Examples include the volume/
mass per surface area, the concentration and the vehicle in 
which the substance is present, the anatomical site, the duration 
of exposure, etc. The resulting, large number of exposure sce-
narios contrasts with the standardized conditions under which 
ex vivo (as well as in vivo) skin penetration testing is performed. 
link information from the protein structure/interaction and cel-
lular levels to the operation of the whole lung (Burrowes et al., 
2008). Multi-scale modeling provides a powerful approach to 
investigate interdependent processes that span many orders of 
magnitude. For example, the interactions responsible for epi-
thelial injury during airway reopening are fundamentally mul-
tiscale, since air-liquid interfacial dynamics affect global lung 
mechanics, while surface tension forces operate at the molecu-
lar and cellular scales. Consequently, a combination of compu-
tational and experimental techniques is being used to elucidate 
the mechanisms of surface-tension induced lung injury (Ghadi-
ali and Gaver, 2008). Computational approaches have also been 
applied to toxicodynamic modeling of silver and carbon nano-
particle effects on mouse lung function (Mukherjee et al., 2013) 
and to uncover underlying mechanisms of disease, such as em-
physema (Suki and Parameswaran, 2014).
4.6  Conclusion
In vitro cultures of pulmonary cells can be used for a wide range 
of scientific and regulatory studies. Even simple models with 
one cell type are of predictive value for many studies; however 
rapid advances in tissue engineering approaches will enable 
development of more complex models that better reflect the in 
vivo situation. Careful phenotyping of cells (passage number, 
calibration of barrier properties, molecular markers) and donors 
(age, clinical characterization, smoking history) is essential, as 
is standardization of methodologies to achieve reproducibility 
of results between laboratories. Access to tissue banks and/or 
stem cell technologies will significantly advance the field (Coz-
ens et al., 1992; Franks et al., 2008; Gruenert et al., 1988; Hall-
dorsson et al., 2007).
5  Regulatory considerations regarding  
non-animal models of biological barriers 
In vitro biological barrier models have been used mainly in the 
pharmaceutical sector, and as yet have not been fully exploited 
and developed to generate information used for chemical risk as-
sessment. When moving from the classical toxicological safety 
assessment based on animal models to approaches using alter-
native methods (in vitro and in silico), toxicokinetics becomes 
a key element to assess systemic effects (Bessems et al., 2014; 
Schroeder et al., 2011). This is particularly relevant for the cos-
metics sector in which an animal-free human risk assessment is 
mandated in the EU (EU, 2009a); however, it is also important 
for other sectors (industrial chemicals, biocides, plant protec-
tion products) in which there is an increasing need for the use 
of non-animal based methods for compound safety assessment. 
Passage of chemicals through biological barriers such as intes-
tine, skin and lung constitutes the first ADME (i.e., absorption) 
process and is the prerequisite for all direct systemic toxicities. 
The rate of absorption will vary depending on the type of chemi-
cal under evaluation, e.g., pharmaceuticals which are designed 
to be absorbed versus industrial chemicals which are not. In this 
regard, knowledge about absorption is very important for proper 
development of intelligent and integrated testing strategies for 
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et al., 2011). A number of difficulties were encountered in such 
investigations: Caco-2 permeability values were not able to be 
obtained for 44% out of 32 tested chemicals due to poor or no de-
tection, lack of stability, and/or lack of available analytical meth-
ods (Prieto et al., 2013). Several compounds (1,2-benzanthra-
cene, phenantrene, hexa-, penta- and tetra-chlorobenzene) were 
excluded from the performed transport experiments due to their 
high lipophilicity, which created problems with respect to solu-
bility and non-specific surface adsorption (Turco et al., 2011). 
5.2.2  Needs
The problem highlighted above is particularly relevant in the 
case of industrial chemicals, as these are frequently lipophilic. 
Additional efforts are therefore needed to change the conditions 
of permeability assays to allow for analysis of lipophilic com-
pounds in such application areas. A suitable strategy to measure 
compound-specific biokinetics (including chemical and meta-
bolic stability, lipophilicity, adsorption to plastics, binding to 
protein) should also be considered as this information would 
prove helpful in data interpretation (Broeders et al., 2012). 
Moreover, there is an urgent need to optimize biobarrier models 
with respect to chemical applicability domains (not only drug-
like chemicals) as well as with respect to the biological response 
domain in the sense that they should be able to quantify ex-
tremely low, low and medium membrane permeability and not 
only high permeability as holds for the Caco-2 cell line. 
As available non-animal biobarrier models may have differ-
ent barrier properties (e.g., transporter expression and level of 
metabolism) in comparison to their in vivo counterparts, it is 
necessary to thoroughly characterize such models in terms of 
metabolic competence and activity of specific transporters, in 
order to determine possible effects on absorption as well as cor-
relation with the in vivo situation. By knowing the differences 
between in vitro and in vivo, the performance of the cellular 
model could be improved by treating cells with known inducers/
inhibitors, or by using complementary in silico tools (Turco et 
al., 2011). The key parameters of a particular biobarrier model 
critical for each application setting also have to be established. 
In general, it would be important to identify a set of chemicals 
with reliable human data to calibrate the model under evaluation. 
It would also be important to have different sets of calibrators 
for different sets of reference chemicals with particular physico-
chemical properties (e.g., industrial chemicals, pharmaceuticals, 
nanoparticles and also for ranges of physicochemical properties 
in general: MW, log Ko/w, pKa, pKb, number of H-donors and 
H-acceptors, etc.). The performance of different barrier models 
with different levels of integration (e.g., PAMPA versus human 
cell models versus tissue) also needs to be compared. 
The biobarrier models should also be optimized if neces-
sary to enable the delivery of information that can be used ul-
timately in the risk management and risk assessment context. 
Approaches developed for this purpose should ideally have a 
clear implementation domain and be designed for straightfor-
ward application in order to keep regulators on board. There 
might be scientific support that the chemical under investigation 
will not be subject to any active transport as the chemical does 
not fit the structural requirements for being a transporter sub-
Therefore, the development – and ultimately validation as a pre-
requisite for regulatory acceptance – of mathematical models 
would be desirable to improve extrapolation from testing condi-
tions to the exposure scenario, thus enhancing the overall utility 
of the method.
5.1.3  In silico models – SAR/QSARs
Although a large number of QSARs have been developed for 
the prediction of dermal absorption, their use is rarely accepted 
in regulatory frameworks. According to the review of an OECD 
working group, the reason for this situation is not solely the lack 
of stringent validation, small training and testing data sets or the 
limited chemical space covered by the model, but, in part, also 
of a technical nature. For example, many QSARs do not take 
into account factors known to influence the extent of dermal ab-
sorption such as the concentration of a substance in its vehicle, 
co-formulants or solvents used, or the amount applied (OECD, 
2011). Furthermore, the currently available QSARs only predict 
Kp values, which are not the relevant endpoint in areas such as 
risk assessment of plant protection products. In the context of 
the COSMOS (Integrated In Silico Models for the Prediction of 
Human Repeated Dose Toxicity of Cosmetics to Optimize Safe-
ty) project, funded by the Seventh Framework Program of the 
European Commission, Gajewska et al. have reported a strategy 
for the oral-to-dermal extrapolation of toxicity data based on 
PBTK modeling using three cosmetic ingredients (coumarin, 
hydroquinone and caffeine) as case study compounds. The 
authors evaluated the role of quantitative structure-property 
relationships (QSPR) as predictors for skin penetration and 
concluded that QSPR provided a reliable alternative to in vivo 
dermal penetration experiments (Gajewska et al., 2014). With 
respect to exposure by potential skin penetration, mathematical 
modeling has already been successfully established in parallel 
to newly developed in vitro systems, with the most recent mod-
els also accounting for the three-dimensional microstructures of 
the skin (Tralau et al., 2015). Such models have been success-
fully established in the R&D environment; however, translation 
into regulatory practice is still needed. 
5.2  Intestine
5.2.1  Acceptance
EURL-ECVAM has been involved in studies of intestinal barrier 
models (Le Ferrec et al., 2001; Zucco et al., 2005) and, in par-
ticular, an ECVAM pre-validation study on in vitro models for the 
prediction of gastro-intestinal absorption was finalized in 2008 
(Prieto et al., 2010). With respect to the oral route, the non-animal 
models available (e.g., Caco-2, TC7 clone) have been used for 
screening purposes for many years, mainly by the pharmaceu-
tical industry as mentioned above. However, the models have 
not been properly evaluated for compounds with relatively poor 
absorption (e.g., below 30% within a short time period). Within 
the framework of the EU ACuteTox project, which aimed to de-
velop a non-animal testing strategy to predict acute oral toxicity 
of chemicals in humans, the suitability of the Caco-2 cell line and 
the TC7 clone for prediction of intestinal transport of selected 
drugs and chemicals was investigated (Prieto et al., 2013; Turco 
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interest in such models in each of the cosmetic/chemical, drug 
and food industries, it would be intriguing to conduct an analy-
sis into why the state of the art, the choice (skin, intestine or 
lung) and the level of model implementation are rather different 
across these three industries.
It is well known that the major drivers for changes in an in-
dustrial context are laws, money and time. In the case of the 
cosmetic industry, efforts to establish alternative testing mod-
els have been driven considerably by the introduction of the 
Cosmetics Regulation (EU, 2009a), which banned animal ex-
periments and literally forced this sector to investigate (and to 
invest!) in alternative testing methods; likewise, the REACH 
legislation with its aim to reduce live animal testing has been 
proven to be a driver for the development and regulatory ap-
plication of alternative testing approaches (EU, 2006; Hartung, 
2010; Tralau et al., 2015). Together with the fact that there had 
already been quite some progress in reconstructing skin equiva-
lents as an alternative to native human skin transplants for treat-
ing severe burns, this has led to the advanced status of non-an-
imal models for safety testing of cosmetics and other topically 
applied chemicals. Similarly, for other toxicological endpoints 
(e.g., skin sensitization, phototoxicity), methods validated by, 
e.g., EURL ECVAM and accepted at an international level (e.g., 
OECD TGs) are in place. Besides the cosmetics sector, the con-
cept of the 3Rs (replacement, reduction and refinement of ani-
mal use) is present in other relevant EU legislation. 
In the case of the pharmaceutical industry, the situation is 
quite different (Rovida et al., 2015). Firstly, testing the safety 
and efficacy of drugs and related products before entering first 
clinical trials in man is not only ethically accepted, but even 
legally requested. For this reason, preclinical R&D – either in 
an industrial or academic context – is typically performed us-
ing animals. A substantial part of serious R&D efforts is even 
made to develop new animal models, especially in the context 
of certain diseases such as cancer, infection or neurodegenera-
tive processes. The expectation in these models is to correctly 
predict both benign and adverse effects of novel therapeutic mo-
dalities when applied to humans. While it cannot be denied that 
animal models have made a major impact on the development 
of new drugs since the beginnings of the pharmaceutical indus-
try and rational drug research, there is also increasing evidence 
that results observed in animal models cannot always be directly 
translated to humans – a fact that has already caused a number 
of major setbacks (Hartung, 2013). 
The need to overcome the intrinsic limitations of any non-hu-
man animal model has perhaps been the major driver in pharma 
to look for human-based – and thus non-animal – in vitro testing 
alternatives. In addition, working with human cells and tissues 
avoids the “black-box effect” of whole animal experiments. 
Such an effect dictates that, while it appears very convincing 
and intuitive when a given treatment shows an improvement of 
characteristic symptoms, a prolongation of lifespan or even a 
curative effect in a particular animal disease model, in the case 
of a negative outcome of such experiments, it is often not easy 
(and at times, may even be impossible) to identify the reason 
for the failure or to suggest rational improvements to either the 
treatment itself or to the testing procedure. This is particularly 
strate (e.g., based on SAR tools that also need to be developed). 
If so, then simple PAMPA models may by sufficient and the use 
of a Caco-2 model or similar superfluous. This also holds for the 
reciprocal situation. There is also ultimately a need for estab-
lishment of a model that mimics not only the cell components 
of the intestine, but also the presence and impact of the com-
mensal microbial population. The diverse commensal micro-
biota harbors a genome a 100-fold the size of its host, providing 
genes for essential functions that the human host is incapable 
of performing, such as vitamin production and metabolism of 
indigestible dietary polysaccharides. 
5.3  Lung
5.3.1  Acceptance
The use of in vitro lung models has been mainly driven by the 
pharmaceutical industry. As such, tobacco and chemical indus-
tries are now investing considerable effort into the evaluation 
and adoption of novel predictive in vitro models for lung toxic-
ity assessment. Among the panel of tests used, in vitro evalua-
tion of xenobiotic permeability is an important piece of infor-
mation in an integrated testing strategy in order to give reliable 
information regarding potential (non)-toxicity upon breathing. 
However, as most of the available models to assess respiratory 
and pulmonary absorption are still under development, no mod-
el has yet found regulatory acceptance.
5.3.2  Needs 
Pulmonary absorption is an area that needs further considera-
tion since no methods that have reached an appreciable level of 
regulatory acceptance are readily available (Adler et al., 2011; 
Bessems et al., 2014). EURL-ECVAM has done some prelimi-
nary investigations on the MucilAir™ in vitro human 3D airway 
epithelium model to assess the inhalation absorption of chemi-
cals; MatTek’s EpiAirway model has also been successfully uti-
lized in several drug delivery applications (Agu et al., 2006; Le-
onard et al., 2007, 2005). Other pulmonary models, such as the 
Calu-3 human bronchial epithelial cell line grown on permeable 
supports at the air interface, and the human alveolar barrier have 
been used to evaluate in vitro pulmonary toxicity (Farcal et al., 
2013; Forti et al., 2011). In this area, the use of more appropri-
ate culturing conditions such as air liquid interface culture and 
the way the cells are exposed should be carefully considered, 
in particular when the tested compound is volatile or insoluble, 
e.g., (nano)particles (Rach et al., 2014; Adamson et al., 2013). 
Ongoing efforts worldwide aim to investigate the application of 
biobarrier models to study the in vitro absorption of nanomateri-
als for safety testing (Ahlberg et al., 2014).
6  Overall Conclusions/Outlook
As the conducted workshop and this resulting report have hope-
fully revealed, non-animal models of epithelial barriers have 
reached impressive levels of technical and scientific sophistica-
tion. Also, their implementation by various industries has made 
considerable progress. While there obviously is considerable 
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tive bioavailability studies on healthy humans) can be obtained 
under certain conditions. Specialized companies have even been 
founded based on in vitro expertise and have established them-
selves as “in vitro CROs” (Goldberg and Hartung, 2008), while 
numerous research activities both in industry and academia are 
currently directed towards better and more complex (e.g., dis-
ease-relevant) in vitro models of the intestinal mucosa. 
It is interesting to note (as alluded to above) that the major 
driving force for implementation of non-animal models in the 
pharmaceutical industry was the clear expectation that utiliza-
tion of in vitro tools would help to accelerate the translation of 
new candidate drugs into clinical trials, and to reduce candi-
date attrition. The same is likely also true for the food industry, 
which has of course witnessed the ongoing development and 
level of implementation of in vitro models in cosmetics and 
pharma. Despite the lack of confinements conferred by a strictly 
regulated registration process (as for pharmaceutical products) 
and the absence of a ban on animal experiments (as for cosmetic 
products), the use of intestinal in vitro models in particular must 
remain of interest in the food industry, offering possibilities to 
investigate and demonstrate the advantages of new diets and 
food processing technologies.
true for research on novel systems and technologies for improv-
ing delivery of APIs across biological barriers, especially when 
the barrier in question is not easily accessible (as in the case 
of the intestinal and respiratory mucosa). The pharmaceutical 
industry has of course noticed and taken advantage of existing 
skin models – the implementation of in vitro skin models for 
the development of transdermal or dermal drug products is in 
fact rather routine, and the obvious advantages of such models 
have initiated and continue to drive further model research and 
development considerably, as seen in this review.
As regards oral drug delivery, which is still by far the most 
preferred route of administering a drug to a patient, the introduc-
tion of the Caco-2 cell line as a model of the intestinal mucosa 
in the late 1980s (Hidalgo et al., 1989) sparked a virtual revo-
lution within the pharmaceutical industry. Optimizing perme-
ability in contrast to receptor affinity according to “Lipinski’s 
rule of five” (Lipinski et al., 1997) has become a well-accepted 
new paradigm in drug discovery for medicinal chemists; such 
in vitro approaches are also widely used in pharma for the ap-
proval of generics, in conjunction with the BCS as pioneered by 
Amidon (Amidon et al., 1995), where so-called “biowaivers” 
(regulatory exemptions from expensive and also ethically sensi-
Fig. 3: Future outlook
The next hurdles to overcome in order to achieve significant reduction and replacement of animal testing are the integration of 
vasculature, immunocompetence, microbiome, and physiological mechanical forces into each barrier model. With specific respect to  
the skin, models with improved barrier function also are required. Combined with organ-specific optimization, this opens the  
floodgates for replacing human disease modeling and delivery testing methods in animals. In parallel, these developments will strongly 
support the multi-organ “human-on-a-chip” concepts aiming to replace systemic animal testing.
Gordon et al.
Altex 32(4), 2015 359
a-chip”) might indeed be practical and useful also remains to 
be seen once the first prototypes of such sophisticated systems 
become available. Indeed, the issues of practicality and useful-
ness must always be considered in any enterprises aimed at in-
creasing model complexity. A cost-benefit analysis must always 
be conducted, involving careful consideration of the extent to 
which it is worth to invest considerable resources to obtain the 
“perfect model” – or whether implementation of rather more 
robust and simple models, which additionally may find greater 
acceptance with industry and regulators, would be of greater 
value. 
Specific mention should also be made here with respect to 
the future development of in silico models of epithelial trans-
port, which, to date, have not evolved sufficiently to be accept-
able from a regulatory point of view (noting, however, that the 
FDA has in progress a number of studies that focus on models 
of various epithelia, with the aim of exploring how such mod-
els may inform the regulatory process). One of the main issues 
that continue to haunt existing in silico modeling is that many 
models, especially early models, are mainly empirical and/or 
statistical in their nature. Another drawback is that many mod-
els are limited to either a single or low number of biophysical 
and biochemical processes of epithelia, while the efficacy and 
safety of epithelia exposure often involves multiple biophysical 
and metabolic processes. The main future challenge of in silico 
modelling is therefore to develop mechanistic multi-scale and 
multi-process models capable of predicting the whole biophysi-
cal and biochemical events of epithelia from source exposure to 
endpoint outcome. Indeed, this is the recent trend in epithelia 
modelling, from molecular dynamics of sub-cellular disposition 
to systems biology of metabolic pathways.
Finally, the development of non-animal models is affected by 
a certain dilemma, which arises from the fact that – in contrast 
to the discovery and creation of novel models – it is not so at-
tractive for academics to validate such models in detail (Har-
tung, 2007), as validation data alone are difficult to publish in 
high-ranking scientific journals. On the other hand, regulatory 
bodies cannot accept any new models until they are properly 
validated. Obviously, academia, regulators and industry must 
therefore collaborate in this respect, and the necessary funding 
to finance such work must also be made available. 
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